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ACTA2 NULL MOUSE.
Carlos Villamizar B.S
Advisor: Dianna M. Milewicz, M.D., Ph.D.

Mutations in ACTA2, the gene encoding for smooth muscle α-actin, predispose patients to a
wide range of vascular diseases and is most commonly associated with thoracic aortic aneurysms
(TAAD) and dissections (TAAD) and strokes. TAAD in patients is characterized by aortic media
degeneration and loss in contractile force generation followed by aortic enlargement and subsequent
rupture. Most stroke cases associated with ACTA2 are described as moyamoya-like cerebrovascular
incidents characterized by distal occlusion of the internal carotid artery, stenosis of arteries in the
Circle of Willis, and straightening of cerebral arteries. Patient samples are scarcely available for
analysis, and the few obtained are from end stages of the disease. For these reason, we decided to
study the causative mechanisms of vascular disease using the

Acta2R258C transgenic and Acta2-/-

mouse models.
The aortic phenotype was studied using the transgenic mouse model bred with Acta2 -/- mice
to decrease the ACTA2 wildtype to mutant ratio. Acta2+/+

R258C TG

mice have decreased aortic

contractility and mild medial wall degeneration but no evidence of aortic enlargement was observed.
However, Acta2+/-

R258C TG

mice showed severe aortic wall degeneration, elastic fiber rupture and

proteoglycan accumulation along with significant aortic dilation. After carotid artery ligation,
Acta2+/-

R258C TG

mice presented with an excessive proliferative response to injury, leading to

increased inflammatory response, unresolved thrombi and severe occlusion of the lumen.

v

Cerebral imaging and histology were studied in WT, Acta2 +/-, Acta-/- mouse mode.
Straightening of the cerebrovascular arteries was observed in Acta2+/- and Acta2-/- mice when
compared with WT mice. Narrowing and/or obstruction of arteries were also present in the Acta2
mutant mice, in particular in the internal carotid arteries.

Histopathologic analysis showed

thickening of the medial layer in both large and small arteries throughout the vasculature with
decreased cell density in the large arteries.
We were able to recapitulate significant characteristics of the aortic and cerebrovascular
pathology seen in patients with ACTA2 mutations in our Acta2 mouse models, proving to be a
valuable tool to study the underlying mechanisms of vascular disease. Furthermore, both aneurysm
formation and SMC proliferative response were exacerbated by decreasing the amount of
endogenous Acta2 in our transgenic model. The severity of the cerebrovascular pathology did not
vary between Acta2+/- and Acta-/-, suggesting a dose dependent effect in these mice. Meanwhile, the
Acta2 R258C mutation appears to have a dominant negative effect, as its effects are inversely
correlated to the amount of endogenous actin in an organism.
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CHAPTER 1
Introduction

1

Arterial Wall Structure and Pathology
Arterial walls are comprised of three distinct layers, the adventitia, media and
intima1-3. The adventitia is made up of extracellular matrix proteins, myofibroblasts,
immune cells and nerve endings (Figure 1.1A). The medial layer is the contractile
component of the wall containing elastic fibers established during development and
consists mostly of differentiated smooth muscle cells (SMCs). The intima is the
innermost layer and is composed of a single cell layer of endothelial cells. A complex
network of collagen fibers helps maintain the wall structure and its elastic properties 4.(8).

2

Figure 1.1: Structural and Pathologic Characteristics of the Aortic Wall - A. H&E
and Movat staining of aortic tissue from control (a,c) and TAA patients (b,d) shows the
three-layer organization of the aortic wall. In control patients, cells are neatly arranged in
layers (a) in-between elastic fibers (c, elastin shown in black). In TAA patients, cells are
disorganized (b), and there is a loss of elastin fibers and accumulation of proteoglycans
(c, proteoglycans appear blue). Republished with permission of Annual Reviews, from
[Genetic basis of thoracic aortic aneurysms and dissections: Focus on smooth muscle cell
contractile dysfunction. Milewicz, D. M., Guo, D. C., Tran-Fadulu, V., Lafont, A. L.,
Papke, C. L., Inamoto, S., Kwartler, C.S. & Pannu, H. 9, 2008]; permission conveyed
through Copyright Clearance Center, Inc. B. Illustration of a lamellar unit, composed of
elastin fibers, single layer of smooth muscle cells and microfibrils linking the cells to the
fibers. Inset illustrates the smooth muscle contractile unit. Adapted with permission of
Annual Reviews, from [Genetic basis of thoracic aortic aneurysms and dissections: Focus
on smooth muscle cell contractile dysfunction. Milewicz, D. M., Guo, D. C., TranFadulu, V., Lafont, A. L., Papke, C. L., Inamoto, S., Kwartler, C.S. & Pannu, H. 9, 2008];
permission conveyed through Copyright Clearance Center, Inc.

There are two types of arteries – small, muscular arteries and large, elastic
arteries. The aorta and common carotid arteries are examples of elastic arteries. In these
vessels, SMCs are organized concentrically around the lumen and encased by layers of
elastic lamellae (Figure 1.1B). SMCs are bound to the lamellae through fibrillin-1
microfibrils at focal adhesion points. The elastic recoil properties of the elastic lamellae
counteract pulsatile blood flow, a critical property of large arteries. In normal arteries, the
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number of elastic layers are determined during development based on the strength of the
pulsatile flow. For example, the ascending aorta has more lamellar layers compared to the
abdominal aorta and carotids4. In contrast, the smaller muscular arteries only have an
internal elastic lamina and external elastic lamina separating the intima and adventitia
from the media, respectively.
Histological examinations of aortic pathology reveal consistent features common
is most diseased aortas. Patients who have suffered dissection, a rupture in the aortic
wall, show clear signs of deterioration of the medial layer: SMC disarray, disruption of
elastic fibers and extracellular matrix degeneration. SMCs in these aortas lose their
concentric organization, leading to regions of both focal loss and gain. Along with SMC
disarray, elastic fiber thinning and fragmentation contribute to weakening of the wall
which results in the loss of its recoil properties5. Previous work has concluded that
increased expression of matrix metalloproteinases (MMPs), zinc endopeptidases,
responsible for extracellular matrix protein cleavage, plays a significant role in medial
degeneration. In the early stages of the disease, cells in the aortic media secrete
proteoglycans, highly glycosylated proteins, as a response to fill in the voids left by the
disruption of the matrix and cell disorganization2-4, 6. Proteoglycan accumulation
progresses along with aneurysm formation (Figure 1.2).
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Figure 1.2: Effects of ACTA2 Mutations in TAAD Patients. Aortic pathology in the
medial layer of patients with ACTA2 mutations. Proteoglycan accumulation is present (in
blue), along with loss of elastin fibers and SMC disarray. From Macmillan Ltd. Guo DC,
Pannu H, Papke CL, Yu RK, Avidan N, Bourgeois S, Estrera AL, Safi HJ, Sparks E, Amor
D, Ades L, McConnell V, Willoughby CE, Abuelo D, Willing M, Lewis RA, Kim DH,
Scherer S, Tung PP, Ahn C., Buja LM, Raman CS, Shete S, Milewicz DM. Mutations in
smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and
dissections. Copyright Clearance Center Nat Genet 2007 December;39:1488-93.

Epidemiology of Thoracic Aortic Aneurysms and Dissections (TAAD)
Thoracic aortic aneurysms and dissections (TAAD) are characterized by a weakening,
enlargement and subsequent rupture of the aortic wall, leading to the creation of a false
lumen disturbing normal blood flow. TAAD has an incident rate of 10.4 per 100,000
people and cause nearly 15,000 deaths every year in the United States, affecting men and
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women equally. Aneurysms are mostly asymptomatic and, if left untreated, it can lead to
dissection, causing death in up to 75% of cases. Due to the high mortality rate,
dissections are treated as medical emergencies and, in most cases, require surgical repair1,
7, 8

.

There are two methods used to classify aortic aneurysms and dissections (AAD) based on
the location of the enlargement and tear in the wall. The first one, the DeBakey system, is
divided into class I, II and III. Class I aneurysms originate at the ascending aorta and can
expand through the descending thoracic aorta. Class II only compromises the integrity of
the ascending aortic wall while class III is localized only in the descending aorta.
Similarly, the Stanford system classifies AAD as Type A or Type B. Type A is a
dissection originating in the ascending or aortic arch and can extend to the descending
aorta, while type B only involves the descending aorta3. (Figure. 1.3)

Figure 1.3: Types Thoracic Aortic Aneurysms and Dissections. A. a. Illustration of
the locations along the aorta where aneurysms commonly occur and b. the Stanford and
DeBakey aortic dissection classification systems. Republished with permission of Annual
6

Reviews, from [Genetic basis of thoracic aortic aneurysms and dissections: Focus on
smooth muscle cell contractile dysfunction. Milewicz, D. M., Guo, D. C., Tran-Fadulu,
V., Lafont, A. L., Papke, C. L., Inamoto, S., Kwartler, C.S. & Pannu, H. 9, 2008];
permission conveyed through Copyright Clearance Center, Inc.

Once a dissections occurs, patients present with a wide array of symptoms
including, but not limited to, significant changes in blood pressure - increases and
decreases based on the location of the dissection - chest and upper back pains radiating to
proximal extremities, numbness, diaphoresis, dyspnea, and loss of consciousness.9,
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Dissections are frequently misdiagnosed, because many of these symptoms overlap with
those of myocardial infarctions. When presenting with these symptoms, it is imperative to
perform CT scans and transesophageal echocardiograms in patients to safely rule out a
dissection. Even if dissections are promptly diagnosed, patients still might not survive the
highly invasive procedure required for its repair. Therefore, it is of crucial importance to
identify individuals at risk prior to the occurrence of a dissection. Standard protocols for
aortic repair are constantly revised due to the genetic and phenotypic heterogeneity of the
disease. When possible, a personalized medical approach is encouraged in these patients
11-13

.

Genetic predisposition is the major risk factor for TAAD, followed by history of
smoking, hypertension, high LDL levels and artherosclerosis. Inherited conditions
include Marfan Syndrome, Vascular Ehlers-Danlos Syndrome, Loeys-Dietz and bicuspid
aortic valves. Patients at risk should be monitored regularly, placed on antihypertensive
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drugs (beta-blockers and/or calcium channel blockers) and are discouraged to engage in
high intensity phyisical activities. Even in the absence of symptoms and genetic risk
factors, smokers are recommended screening between 60-75 years of age14-16. As we
learn more about TAAD, the focus has shifted from repair to early detection, prevention
and management of the disease15.

Genetic Basis of TAAD
Initially, TAAD was associated with various connective tissue disorders, mainly
Marfan Syndrome and vascular Ehlers Danlos Syndrome. Additional syndromes, such as
Loeys-Dietz, were later identified by mutations in key players of the TGF- pathway.
These account for roughly 5% of all TAAD cases. More recently, mutations causing nonsyndromic TAAD have been discovered. Inherited mutations, termed familial TAAD
(fTAAD) account for 15% of cases, while the other 80% is attributed to sporadic
occurrences (sTAAD)16-18.

Connective Tissue Disorders Causing Aortic Aneuryms and Dissections
Marfan Syndrome is the most common connective tissue disorder associated with
TAAD, affecting one out of five thousand people in the United States19, 20. Diagnosis
criteria for this disease include a wide range of abnormal skeletal features (long elastic
limbs, tall stature, scoliosis, high arched palate, pectus excavatum or carinatum) along
with ectopia lentis (lens dislocation) and aortic enlargement. Dominant mutations in
FBN1, a gene coding for ECM protein fibrillin, were identified to be the cause of the
disease3, 21, 22
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Microfibrils connecting the SMCs to elastic fibers in the arterial wall are
constituted mainly of fibrillin.

In normal conditions, fibrillin sequesters TGF-B1,

rendering it inactive. When there is a defect in the protein, TGF-β1 is released and
signaling enhanced. Several studies have suggested increased TGF-B1 signaling in SMCs
and myofibroblasts to be one of the driving forces behind aneurysm formation23-25.
Promising studies in Marfan mouse models have indicated that treatment with
angiotensin II type I receptor (ATRI) blockers, commercially known as losartan and
pravastatin, are able to prevent aneurysm formation. Further studies are required to
establish the connection between ATRI and regulation of the TGF-B pathway23, 26.
A less common disorder, vascular Ehlers Danlos Syndrome (vEDS) is caused by
mutations in COL3A1, a gene encoding for procollagen33. Patients present with impaired
wound healing, clear transluscent and elastic skin, increased joint flexibility and various
other skeletal features. Arterial dissection is the only life-threatening symptom of the
disease and, contrary to the other syndromes, dissection may occur without prior
dilatation. Environmental risk factors such as smoking, extreme physical activity and
hypertension, have been suggested as triggers of spontaneous dissections in these
patients. Therefore, early detection of mutations in COL3A1 is imperative for proper
disease management 27-29.
Even though Loeys-Dietz Syndrome is not caused by alterations in connective
tissue proteins, it does present overlapping features with Marfan Syndrome. Mutations in
TGFBR1 and TGFBR2, major players in the TGF-B pathway, have been linked to the
disease. Patients suffering from this syndrome present with similar skeletal and
cardiovascular abnormalities as those with Marfan Syndrome along with cleft palate,
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thinned skin, and bifid uvula. The overlap of features is expected based both being caused
by dysregulation of the TGF-B signaling pathway3, 30.

Non-Syndromic TAAD
Patients with early onset non-syndromic TAAD without prior family history are
described as sporadic cases. Accounting for nearly 80% of all incidents, these patients are
probably victims of old age, environmental risk factors (i.e obesity and smoking), rare
genetic variants and/or de novo mutations3, 31. Because of the asymptomatic nature of
aneurysms and lack of established methods for early detection, these patients suffer a
greater risk of dissection.
Recently, focus has shifted to genetic risk factors known as “rare variants.” These
non-synonymous variants do not segregate in a Mendelian manner but are more frequent
than single nucleotide polymorphisms (SNPs) in patients with TAAD. It is believed these
variants predispose patients to aortic disease but not without the presence of additional
risk factors. Our lab has identified a missense R247C rare variant in MYH11, a gene
coding for smooth muscle myosin, which is a key component of the contractile apparatus
in SMCs. Studies suggest this alteration causes a 10-12 fold increased risk of aortic
disease. Additionally, kinetics studies of the myosin motor showed a decrease in ATPase
activity in R247C mutants when compared to controls. A knock-in mouse model of
MYH11 R247C was created to further understand the role this variant plays in aortic
pathogenesis. Although there seemed to be no significant enlargement of the aorta, ex
vivo contractility studies confirmed decreased force generation in mutant aortic rings.
Explanted murine aortic SMCs were dedifferentiated and more proliferative when
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compared to controls. To corroborate these findings in vivo, left carotid artery ligations
were performed in both MYH11 R247C and WT mice. Analysis of the vascular injury
showed increased medial thickening and enhanced neointimal formation. These results
suggest that even in the absence of aortic disease, R247C mutations do have an impact in
the contractile apparatus as well as in cellular response to injury31, 32.
Genome-wide association studies have been used to identify genetic variants
responsible for sTAAD. A total of 765 sporadic cases and 874 controls were compared
identifying SNPs at a 15q21.1 locus associated with sTAAD. These SNPs fall into the
region including the FBN1 gene. Interestingly, mutations in the FBN1 gene cause Marfan
syndrome. The study suggests that variants in this region act via FBN1, leading to similar
aortic pathogenesis between Marfan syndrome and sTAAD 33.

Familial Thoracic Aortic Aneurysms and Dissections (fTAAD)
Much of our effort has been focused on identifying single gene mutations
inherited in a Mendelian manner responsible for familial cases of TAAD. Accounting for
15-20% of all cases, these mutations are heterozygous, dominant negative and have
variable expression with decreased penetrance3, 16, 34. Earlier studies in syndromic TAAD
have identified mutations in the TGF-B1 pathway as key culprits of aortic disease. Not
surprisingly, genes in this pathway (TGFBR1/2, SMAD3, TFG-B1,) were also found to
be the cause non-syndromic fTAAD35-39. Using a similar approach, genes of the
contractile SMC apparatus were screened in the patient population. So far, deficiencies in
three contractile genes (MYH11, MLCK and ACTA2) have been identified to cause
fTAAD3, 40, 41.
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Mutations in TGF-B1 Pathway associated with TAAD
The TGF-B superfamily includes three distinct ligands crucial for a range of
cellular pathways. In SMCs, it is a key component in several processes including
proliferation, migration and differentiation. When TGF-1 binds to a heterodimer of
TGF- receptors, TGFBR1/2, these tyrosine kinase receptors phosphorylate each other
and downstream targets. The canonical pathway involves the activation of the SMAD
family in response to TGF- signaling. SMAD2/3 are activated and subsequently bind to
SMAD4, which translocates the complex to the nucleus, activating a large number of
downstream target genes. Simultaneously, TGFBR1/2 can also activate a “noncanonical” pathway independent of SMAD signaling, having mitogen-associated protein
kinases (MAPKs) as the primary targets42, 43.
In normal cells, TGF- signaling induces contractile gene expression, mainly
ACTA2 and MYH11, driving SMC differentiation. In patients with TGFBR1/2 mutation,
isolated SMCs in vitro are characterized by poor contractile filament formation and
appear to be in a constant de-differentiated state. Alterations in TGFBR2 appear to have
no effect in the canonical signaling, but there is a clear disruption of the MAPK
pathway39,

44

. Clearly, in vitro studies indicate a loss of function in patients with

TGFBR1/2 mutations. Paradoxically, immunohistochemical analysis of diseased aortas
shows an increase in phosphorylated SMAD2/3. The contradicting results suggest that
mutations in these receptors do cause a loss of function, but in vivo, through a yet
12

unknown mechanism, TGF- signaling is increased leading to increased SMAD
activation. Therefore, some scholars consider these alterations as “gain-of-function”
mutations39, 45.
Contractile Gene Mutations
The contractile apparatus is a paramount constituent of SMC function. Therefore,
a disruption of any of its major components has the ability to hamper SMC contractility
and subsequently weaken the aortic wall. Thus far, mutations have been identified in
three contractile genes: MLCK, MYH11 and ACTA23, 41. We will focus on the latter two.
MYH11 and ACTA2 code for smooth muscle myosin and -actin, respectively.
During contraction, calcium-activated phosphorylation of myosin filaments causes
binding to actin through rapidly cycling cross-bridges, leading to contraction and force
generation. Therefore, any disruption in the cyclic interaction between these two
molecules can lead to detrimental effects in arterial function. Mutations in MYH11 have
been associated with fTAAD and vascular occlusive diseases along with patent ductus
arteriosis (PDA), where the fetal connection between the aorta and pulmonary arteries
remains open after birth. Analyses of patient’s aortas show classic medial degeneration
including proteoglycan accumulation, SMC hyperplasia and disarray, and elastic fiber
deterioration40,

46

.

Occlusion of the vasa vasorum in the aortic wall suggests a

proliferative pathology caused by SMC hyperplasia in smaller vessels47.
Mutations in ACTA2 are the most common cause of fTAAD, accounting for 13%
of all familial cases47, 48. Patients with ACTA2 mutations present with similar aortic and
vascular occlusive pathology (strokes), but no association with PDA was found. Unique
to these families, is the segregation of coronary artery disease (CAD), livedo reticularis
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(occlusion of dermal vessels), early-onset stroke and Moyamoya-like disease. A total 16
mutations have been identified in ACTA2, each with distinct penetrance and vascular
occlusive presentations. For example, 30% of individuals with R118Q mutations were
associated with early on-set CAD, but low frequency of strokes. In contrast, patients with
R258C/H had a 6.51-fold increase risk of stroke when compared to other ACTA2
mutations47, 49.
Mutations in ACTA2 Cause Global Vascular Dysfunction.
As previously described, mutations in ACTA2 cause the most severe aortic and
vascular occlusive phenotypes in patients with fTAAD. For that reason, our lab has
focused on identifying the molecular mechanisms of vascular pathogenesis using patient
samples, in vitro analyisis and murine disease models of ACTA2 mutations.
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Figure 1.4: Characteristics of SMCs in Patients with Alterations in ACTA2 - A.
SMCs from patients with ACTA2 mutations have disrupted α-actin filament formation.
Adapted by permission Copyright Clearance Center: Nature Genetics, copyright (2007)
B. Explanted SMCs and dermal fibroblasts from patients with ACTA2 mutations
proliferate more than control cells in culture. Reprinted from The American Journal of
Human Genetics, Dong-Chuan Guo, Christina L. Papke, Van Tran-Fadulu, Ellen S.
Regalado, Nili Avidan, Ralph Jay Johnson, Dong H. Kim, Hariyadarshi Pannu,
Marcia C. Willing, Elizabeth Sparks, Reed E. Pyeritz, Michael N. Singh, Ronald L.
Dalman, James C. Grotta, Ali J. Marian, Eric A. Boerwinkle, Lorraine Q. Frazier,
Scott A. LeMaire, Joseph S. Coselli,

Anthony L. Estrera, Hazim J. Saﬁ, Sudha

Veeraraghavan, Donna M. Muzny, David A. Wheeler, James T. Willerson, Robert K.
Yu, Sanjay S. Shete, Steven E. Scherer, C.S. Raman, L. Maximilian Buja, and Dianna
M. Milewicz, Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause

Coronary

Artery Disease, Stroke, and Moyamoya Disease, Along with Thoracic Aortic Disease,
617-627, Copyright (2009), with permission from The American Society of Human
Genetics.

In individuals with ACTA2 mutations, we see classic markers of aortic disease.
At the molecular level, explanted SMCs from affected aortas show different degrees of
disruption of -actin polymerization based on the location of the mutation (Figure 1.4A).
To study a wider array of mutations, dermal fibroblasts were explanted from ACTA2
mutation carriers.

Even after treatment with TGF-B1, which induces expression of

contractile genes and differentiation, these cells were unable to produce healthy actin
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filaments. Proliferation assays were then performed to corroborate the proliferative
phenotype observed in patient aortas. As expected, both SMC and dermal fibroblasts
showed an increased proliferative response when compared to controls. (Figure 1.4B).49
These observations suggest that in smaller contractile vessels (i.e distal end of internal
carotids), disruption of actin filaments leads to increased SMC proliferation in vivo as a
compensatory mechanism; supporting our hypothesis of SMC hyperplasia as the main
cause of the stenotic lesions seen in patients with livedo reticularis, CAD, stroke and/or
MMD48, 49.

ACTA2 and Moyamoya Disease
Moyamoya disease (MMD) affects 1 in 119,000 people in the United States alone.
Diagnosis is based on cerebrovascular imaging of bilateral stenosis of the distal internal
carotid arteries with an abnormal vascular network surrounding the lesions50. Occlusion
of the ICAs and weakness of the collateral circulation can lead to ischemic and
hemorrhagic strokes as early as the first decade of life51. There are two different postischemic surgical methods to treat for MMD: direct and indirect revascularization. The
most common direct procedure is a superficial temporal artery to middle cerebral artery
anastomosis which induces intracranial neovascularization and helps prevent future
ischemic attacks. Indirect revascularization methods use richly vascularized tissue and
attach it to areas of lesion in the cortex, such as inversion of the dura
(encephalodurosyangiosis). Proponents of this method claim low post-operative
morbidity, mortality and decreased incidences of recurrent strokes 52-54.
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Given the severity of MMD, much emphasis has been placed on finding the
genetic contributors of the disease. MMD has been associated with numerous genetic
disorders including: Marfan Syndrome, neurofibromatosis, Ehler-Danlos Syndrome and
Down Syndrome among others55. Non-syndromic familial cases have been identified in
patients with mutations in ACTA2, RNF213 and Xq28 deletions56-58.
Initial screenings identified two mutations in ACTA2 at the SM -actin SD4
domain, R258C/H and R212Q, responsible for TAAD, stroke and MMD49. Recently, a
third, de novo mutation in ACTA2, R179H, was associated with an early onset severe
phenotype caused by global smooth muscle dysfunction. Patients with this mutation
present

with persistent

ductus

arteriosis,

congenital

mydriasis,

bladder

and

gastrointestinal deficiencies, and pulmonary hypertension. Interestingly, these patients
have a Moyamoya-like cerebrovascular presentation that includes occlusion of the distal
ICAs and abnormally straight course intracranial arteries, but without the typical
“moyamoya” collaterals58. Stenosis in ICAs occurs at the level in which the arterial wall
changes from elastic to muscular, increasing the susceptibility of this area to changes in
vascular pressure and fluid dynamics leading to proliferative vascular occlusive lesions.
Interestingly, similar pathology is thought to cause stroke in other patients with ACTA2
mutations that did not meet the criteria for MMD51, 59.

Acta2 Mouse Models
ACTA2 has become a prime candidate gene to study vascular diseases because of
its early phenotypic presentation and widespread SMC dysfunction. Challenges arise
when studying the vascular pathogenesis of ACTA2 mutations using patient samples.
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First, patient samples are not readily accessible. Also, these samples are only obtained in
the end-stages of disease, rendering it impossible to observe the causative mechanisms of
the disease. For these reasons, we decided to look at vascular pathogenesis in two mouse
models, Acta-/- and a transgenic Acta2 R258C model60. We started working on
developing an R179H knock-in mouse model as well, the most severe ACTA2 mutation,
but it has been technically challenging.
Analysis of the Acta2 null mouse model determined that -actin is not necessary
for cardiovascular development and has minor effects in the digestive and reproductive
systems61. Even though SM -actin is the most abundant protein is mature SMCs,
increased levels of skeletal -actin, usually not expressed in SMCs, might explain the
viability of this model. However, impaired vascular contractility and tone and decreased
blood pressure were observed in these mice61. Furthermore, evaluation of Acta2-/- aortas
found an abnormal aortic wall structure starting at one month of age. The average
number of elastic lamellae increases from 7.5, in WT aortas, to 11, in null aortas 60.
Quantitation of cells in the aortic wall showed increased density of SMCs in the Acta -/mice (Figure 1.5A)60. The increased number of elastic fibers and cell density suggests a
compensatory mechanism for the loss in contractility. By three months of age, significant
enlargement of the ascending aorta is observed in the absence of Acta2 and by 12 months
of age the wall presents with the classic markers of aortic disease. Medial thickening with
increased expression of Mmp2 leading to elastic fiber disruption and proteoglycan
accumulation was observed60 (Figure 1.5B). These results mirror the pathology present
in the aortic wall of patients with ACTA2 mutations47, 49.
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Figure 1.5: Aortic Pathology in the Acta2-/- Mice - A. Thickening of the media,
increased number and fragmentation of the elastic lamellae are observed in Movat stains
of aortic cross-sections. B. Acta2-/- mice present with enlarged aortas at 2 months of age,
increased SMC density at birth and thicker media after 12 months of age 60.

A transgenic mouse model of R258C was generated in the Milewicz lab to further
understand and characterize one of the most severe dominant negative mutations in
Acta2. A cDNA construct of the Acta2 gene, including the R258C mutation in exon 7 and
the endogeous Acta2 promoter, was generated and inserted into a C57Bl/6 background. In
parallel, a second transgenic line using the same construct was generated to assure that
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the observed phenotype was caused by the mutation itself and not by the site of insertion.
Confirmation of the mutant gene transcription was achieved through quantitative realtime PCR (Figure 1.6A). Construct was made by Dr. Kuang in the Milewicz Lab.

Furthermore, confirmation of protein expression was confirmed by isoelectric focus (IEF)
blot using aortic protein lysates.60 (Figure1.6B).
Figure 1.6: Generation of the Acta2R258C Transgenic Mouse Model - A. Construct
design for mutant transgene, containing a wildtype α-actin promoter up to intron 160. B.
IEF blot confirming mutant (R258C) α-actin expression in the aorta66.

The focus of the thesis will be to characterize the dominant negative effect of the
Acta2 R258C mutation in the transgenic mouse model and study the cerebral vascular
occlusive pathogenesis in the Acta2 null model. Furthermore, we believe that decreasing
the wildtype:mutant actin ratio increases phenotypic presentation of the disease.
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CHAPTER 2
Materials and Methods
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Mouse Breeding Scheme
Pure C57Bl/6 background male Acta2-/- mice were crossed with Acta2+/+
mice. The resulting pups were Acta2+/- and Acta2+/-

R258C

R258C

female

. The resulting Acta2+/-

females were mated with Acta2-/- males (Figure 3.2). No Acta2-/-

R258C

R258C

mice reached

weaning age. (Table 1 Supplement)

Murine Echocardiography
Echocardiography of the the aortic root and ascending aorta were performed on gender
and age matched Acta2+/+ R258C, Acta2+/- R258C, Acta2+/- and wildtype control mice
to determine aortic diameter. We use the Vevo 770 40MHz ultrasonic probe
(VisualSonics Inc., Toronto, Ontario, Canada) to follow aortic diameter at 1 month, 3
months, 6 month and 1 year of age. Measurements of the aortic root and ascending aorta
were obtained in late diastole at the parasternal long-axis view. Analysis was performed
using the Vevo 770 Software.

Aortic histology and analysis
Mice were anesthesized using 0.7cc of 2.5% avertin. The chest cavity was then exposed
and a 271/2 gauge needle inserted into the left ventricle. Using the Masterflex C/L Pump
(Cole-Palmer, 625 East Bunker Court, Vernon Hills, IL 60061) to control for rate
(5ml/min), the mouse was perfused using 10ml Dulbecco’s PBS, followed by 10ml of
10% neutral buffered formalin. The lungs were extracted and the aorta was carefully
dissected in situ. Once clean, the aorta was explanted, cut at the root and arch distal to the
left carotid (2mm of each carotid were kept for orientation purposes), and stored in 10%
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formalin overnight. The tissue was then subjected to a series of dehydrating washes (20
minutes each) using 50%, 70%, 85%, 95%,100% ethanol and 100% histoclear. Aortas
were then incubated in melted paraffin at 60o C for 1 hour before being embedded in
paraffin blocks.
Sectioning of the paraffin blocks was done at 5um per section using the Olympus 4055
Microtome (Olympus America Inc. Center Valley, PA 18034). Standard protocols were
used for MOVAT pentachrome and hematoxylin and eosin staining.
Images were taken using Olympus DP-71 Digital Camera and BX-60 Microscope
(Olympus America Inc. Center Valley, PA 18034) at 40x, 100x, 200x and 400x
magnification. All histological data collection and analysis was done using Image J
software (NIH). The color threshold tool was used to count pixels for elastin (black),
proteoglycans (blue) and SMCs (red). Quantification of the elastin breaks were done by
visual inspection.

Western blot assays
Mice were anesthesized using 0.7mm3 of 2.5% avertin. The chest cavity was exposed,
the thoracic organs extracted and the aorta was carefully dissected. Once explanted, the
aorta was cleaned in Dulbecco’s PBS and snap frozen in liquid nitrogen. The tissue was
homogenized using a Fisherbrand handheld homogenizer in RIPA buffer, protease
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and phosphatase inhibitor cocktail
(Sigma-Aldrich, St. Louois, MO). 5 μg of protein isolate for each sample were separated
by SDS-PAGE on Tris-HCL gel (Bio-Rad, Hercules, CA) and transferred on
polyvinylidene difluoride membranes at 80Vfor 90 minutes. (Milliford, Bedford, MA).
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Immunoblots were achieved using primary antibody (incubated 3 hours at 25 oC). The
membrane was then incubated for 1 hour in the corresponding horseradish peroxidase
secondary antibody (Jackson Laboratories, West Grove, PA). Chemiluminescence (GE
Healthcare, Piscataway, NJ) was used to visualize immunoblots.

Contractility assays
Fourteen week old mice were anesthetized using 2.5% avertin. Aortas were dissected (see
method above), cut into 3mm rings, weighed and mounted on wire triangles. The tissue
was placed on an isometric force apparatus, equilibrated and stretched to 1.8g. After the
initial stretch, the tissue was allowed to recover for 45 minutes. A buffer imitating
physiogical conditions (118.5mM NaCl, 4.75mM KCl, 1.2mM MgSO4, 1.2mM
KH2PO4, 24.9mM NaHCO3, 1.6mM CaCl2, 10.0mM D-glucose, pre-gassed with 95%
O2/5% CO2 at 37°C) was used during the recovery periods. Aortic rings were subjected
to four rounds of stimulation with KCl (90mM), 5 minutes per round. A 5-minute
recovery period was allowed after each round. After the final round, a second 45-minute
recovery period was allowed and then a final stimulation with 10mM phenylephrine for 5
minutes was performed.

Carotid artery ligation
Left carotid artery ligation flow-cessation model was performed on 8-week-old WT,
Acta2+/-, Acta2-/-, Acta2+/+ R258C and Acta2+/- R258C mice. Mice were anesthetized
using 2% isofluorane through nosecone inhalation. The left common carotid artery was
ligated 1-2mm from its bifurcation using 5-0 silk suture. Animal survival rate was > 95%.
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Mice were sacrificed 21 days post ligation and both carotids harvested. The entire length
of the left and right carotid arteries was sectioned (at 5um per section) and examined for
identification of the site with most significant thrombus formation and stenosis. Carotid
artery tissues were stained using standard protocols. Specimens were imaged and
photographed using an Olympus microscope. For morphometric analyses, images of
H&E stained cross-sections of injured and control arteries were analyzed using Image J
(NIH). Perimeters of the lumen, internal elastic lamina and external elastic lamina were
obtained by tracing the contours on digitized images using ImageJ software.
Neointimal/thrombus and medial areas were calculated. Percent lumen stenosis was
calculated using the formula: thrombus area/lumen area × 100.

Irradiation and Bone Marrow Transplant
At 6 weeks of age, wildtype and Acta2-/- mice were irradiated using the RS2000
Biological Research Irradiator (RAD Source Technologies, Suwanee, GA). Mice were
irradiated in two separate sessions, 3 hours apart at 500 rads each, for a total of 1000 rads.
Five million bone marrow cells from C57Bl/6J UBC-GFP (Jackson Laboratory, Bar
Harbor, ME) were transplanted through intraocular injection using a 28 1/2 -gauge needle 4

hours post irradiation. Mice were placed in a sterile room and fed sterile food and water.
Baytril (0.5mg/ml) was administrated in the drinking water to prevent bacterial
infections. Mice were monitored twice daily, weighed and assessed for irradiation
poisoning for 14 days. Three weeks post irradiation, carotid ligation was performed and
carotids harvested after 21 days for analysis (as indicated above).
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Bone Marrow Stem Cell Isolation
C57Bl/6J UBC-GFP (Jackson Laboratory, Bar Harbor, ME) male mice 8-10 weeks of age
were anesthesized using 0.7mm3 of 2.5% Avertin. The mice were sacrificed by cervical
dislocation and the lower limbs removed at the hip joint. The femur and tibia were
carefully dissected removing skin and muscle tissue and placed in a culture dish with
RPMI-1640. The ends of the bones were cut and bone marrow flushed with a 27-gauge
needle containing 10mls of RPMI-1640. The media with the bone marrow was then
passed through a 22-gauge needle to break tissue clumps. Cells were separated from the
remaining solution using BD-40um strainers. Cells were then centrifuged at 100g for 10
minutes and rediluted in PBS with a final concentration of 50 million cells/ml.

Brain Imaging
All in vivo procedures were approved by the Baylor College of Medicine IACUC
and Imaging was provided by Dr. Annapragadas Lab. A novel liposomal CT contrast
agent (~120nm particle size, PEG surface coating, total iodine ~150 mg/ml, dose~6uL/g)
was injected via tail vein into test animals. Animals were anesthetized by isoflurane
inhalation and maintained on 0.2-0.4% isoflurane delivered by face-cone. A low
resolution pre-contrast scan was conducted to verify and record the presence of any
radioopaque structures. The contrast agent was then injected (~8µL/g) via tail vein. For
low resolution (38µ isotropic voxels) the following parameters were used: 60kVp,
400µA, 360 projections, 850ms exposure. For high resolution (19µ isotropic voxels) the
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following parameters were used: 60kVp, 500µA, 1440 projections, 850ms exposure
(Figure 2.1).

Figure 2.1 Diagram of the Circle of Willis. (Left) Diagram showing all vessels
analyzed around and within the Circle of Willis. (Right) Dimensional Parameters of the
Circle of Willis. With permission from60.

Automated scripts were written in Matlab (Version 7, Mathworks Inc., Cambridge
MA) for these calculations. Vessels were segmented using the intensity-gradientmaximum technique to identify the vessel margin in the radial direction. Centroids of the
vessel boundary shape in each section were connected to approximate the centerline of
the vessel, from which all distance and area measurements were made. The following
data was collected:
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1. Vessel diameters: were approximated as the diameter of the circle of equal area to each
section, from which a mean diameter was calculated.
2. Vessel (Arc) length: approximated as the sum of the linear distances between centroids
of each section.
3. Vessel curvature was measured by 3 parameters: (a) The Cauchy curvature for a
concave segment was estimated by drawing normals to the centerline curve at its end
points, and calculating the radius of curvature by calculating the intersection of the
normals. (b) The Arc-to-length ratio of a segment and (c) the Inflexion count,
measuring the number of locations where the concavity of the vessel changed
direction. Thus, the Cauchy curvature assumed the segment was singly concave, the
arc-to-length ratio permitted muFltiple concavities, and the Inflection count measured
the number of concavities. Since some vessels exhibited straightening at the ends of
the segment while curvature persisted at the center, we defined the “middle curvature”
as the Cauchy curvature of the central third of the segment, and reported it as a
separate parameter.
4. The intercarotid distance and the width of the Circle of Willis were measured as the
Euclidean distance between the proximal ends and the distal ends of the internal
carotids, respectively.
5. The area of the Circle of Willis was measured by the area of its projection on the
coronal plane. The Circle of Willis was then divided into an upper-half, and a lowerhalf, using the line that connected the proximal ends of the internal carotids as the
divider. The areas of the two halves were measured in the coronal plane.
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6. Basal Triangle Area: An additional measure of the area was based on the area of the
triangle formed by the distal end of the basilar and the proximal ends of the two
internal carotids, in its own plane.
7. Narrowing Count: As an indication of the number of incidences of a narrowed vessel,
the fraction of segments with diameter lower than 85% of the mean diameter was
calculated.
8. Mean circularity: In the cross-sectional plane normal to the centerline, the circularity
was calculated as the ratio between the contour area and area with a circle with radius
R, where R is calculated based on circumference of contour. The mean was calculated
over the set of individual circularities.
9. Mean aspect ratio: The aspect-ratio was defined as the ratio of first and second
eigenvalues calculated on the contour at a point on centerline.

The mean was

calculated for a set of individual aspect ratios.

Cerebrovascular histology and analysis
At 16 weeks, female WT, Acta2+/-, Acta2-/- mice were anesthesized using
0.7mm3 of 2.5% avertin. The chest cavity was then exposed and a 27 1/2 gauge needle
inserted into the left ventricle. Using the Masterflex C/L Pump (Cole-Palmer, 625 East
Bunker Court, Vernon Hills, IL 60061) to control for rate (5ml/min), the mouse was
perfused using 20ml Dulbecco’s PBS, followed by 20ml of 10% neutral buffered
formalin. Following perfusion, the head was severed, the brain carefully extracted and
stored in 10% formalin at 4oC overnight. The tissue was then subjected to a series of
dehydrating washes (45 minutes each) using 50%, 70%, 85%, 95%, 100% ethanol, 50/50
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histoclear ethanol mixture, 100% histoclear,. Brains were then incubated in a melted
mixture of 50/50 histoclear and paraffin at 60o C for 30 and finally in pure paraffin for 1.5
hours before being embedded in paraffin blocks.
Brain sections (5um) were collected every 120um using the Olympus 4055
Microtome (Olympus America Inc. 3500 Corporate Pkwy, Center Valley, PA 18034).
Standard protocol was used hematoxylin and eosin staining. Images were taken using
Olympus DP-71 Digital Camera and BX-60 Microscope (Olympus America Inc. Center
Valley, PA 18034) at increasing magnifications - 40x, 100x, 200x and 400x. Vessel
measurements obtained with ImageJ v1.47 (NIH, Bethesda, MD) were used to calculate
wall-to-lumen ratio (WLR=wall thickness/(diameter-2 x wall thickness)) and percentage
wall thickness (%TH=[(2 x average medial thickness)/external diameter] x 100)

62 63, 64

.

Vessels in all regions of the brain of the mice were divided into groups by the lengths of
their short diameter (100-200µm and >200µm).

Smaller arteries in the cerebral

parenchyma (diameter < 100µm) could not be accurately assessed using %TH and WLR
and were classified as “normal” or “thickened”.
To assess SMC hypertrophy of the medial layer, measurements were made on
cross sections of arteries (Diameter > 100 µm) for the WT and Acta2-/- mice. Density of
cells in the media was calculated by counting the SMC nuclei in the media and dividing
by the vessel wall area.

Statistical analysis
For CT based vascular morphometry the Kolmogorov-Smirnov test was used to
assess normality and all distributions failed the test. Therefore, the Kruskal-Wallis test
was used to compare groups. Statistical significance in inter-group differences was
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assessed at the 95% confidence level (p<0.05). All statistical calculations were performed
in Matlab (Version 7, Mathworks Inc., Cambridge MA).
Data from pathological measurements were tested for normality using the
Shapiro-Wilk test. When data were normal, one-way analysis of variance (ANOVA) was
performed, and pairwise multiple comparisons were performed using Bonferroni multiple
comparison procedures.

When data failed the equal variance test, Kruskal–Wallis

ANOVA on Ranks was performed and pairwise multiple comparisons were made using
the Dunn’s method. Cell density data were both analyzed non-parametrically by the
Mann-Whitney U test, followed by independent t test using SPSS 22.0.0 (Statistical
Package for the Social Sciences, Chicago, IL). Analysis provided by Dr. Annapragada’s
Laboratory, Texas Children’s Hospital and Baylor College of Medicine.
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CHAPTER 3
Characterization of the Acta2R258C Mouse Model Aortic Phenotype
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Introduction
Analysis of the Acta2-/- mouse model gave us an insight into the effects of the loss of actin in the vascular system. Mutation in patients with ACTA2 mutations are expected to
have a dominant negative effect; therefore, we predict that a mouse model harboring an
Acta2 mutation will have similar vascular pathogenesis. As a result, we chose to study the
vascular effects of ACTA2 R258C mutation. Patient families that were originally
identified to carry the ACTA2 R258C alteration, showed that 70% of mutation carriers
developed TAAD and 50% of cases suffered early on-set strokes49. (Figure 3.1)

Figure 3.1: ACTA2 R258C mutation causes TAAD and Stroke. Reprinted from The
American Journal of Human Genetics, Dong-Chuan Guo, Christina L. Papke, Van TranFadulu,

Ellen S. Regalado,

Nili

Avidan,

Ralph Jay Johnson,

Dong H. Kim,
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Hariyadarshi Pannu, Marcia C. Willing, Elizabeth Sparks, Reed E. Pyeritz, Michael N.
Singh, Ronald L. Dalman, James C. Grotta, Ali J. Marian, Eric A. Boerwinkle,
Lorraine Q. Frazier, Scott A. LeMaire, Joseph S. Coselli, Anthony L. Estrera, Hazim J.
Saﬁ,

Sudha

Veeraraghavan,

Donna M. Muzny,

David A. Wheeler,

James T.

Willerson, Robert K. Yu, Sanjay S. Shete, Steven E. Scherer, C.S. Raman, L.
Maximilian Buja, and Dianna M. Milewicz, Mutations in Smooth Muscle Alpha-Actin
(ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease, Along with
Thoracic Aortic Disease, 617-627, Copyright (2009), with permission from The
American Society of Human Genetics.

Due to the severity of the disease, a transgenic mouse model with an Acta2
R258C mutation was generated to deepen the understanding of its role in aortic
pathogenesis, both in vitro and in vivo60. Furthermore, we hypothesize that a decrease of
endogenous Acta2 expression would increase the severity of the phenotype in these mice.
Therefore, we developed a breeding scheme by crossing our transgenic mouse with the
-/-

+/+

+/+ R258C

Acta2 null model, that yielded 4 genotypes Acta2 , Acta2

, Acta2

+/-

and Acta2

+/-

R258C

. (Figure 3.2A). Furthermore, we used aortic explants from Acta2-/- R258C embryos –

these mice were not viable postnatally – to test the expression of mutant smooth muscle
a-actin (Figure 3.2B).
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Figure 3.2 Acta2+/-

R258C

Mice Breeding Scheme - A. Breeding scheme to decrease

endogenous Acta2 expression. B. Immunoblot showing α-actin expression in aortic tissue
from Acta2-/- R258C TG mice.

Aortic lysates from all four genotypes were used for in vitro studies. cDNA from
SMC generated for Quantitative PCR show a significant increase in all smooth muscle
contractile gene expression in Acta2+/+ R258C cells when compared to wild type. Similarly,
Acta2+/-

R258C

show significant increases in calponin 1 (Cnn1) and MYH11, but no

difference in Acta2 and SM22a expression (Figure 3.3A). Acta2+/- cells did not seem to
have differences in contractile gene expression when compared to controls (Figure 3.3A).
Analysis of contractile protein expression showed similar increases in Acta2

+/+ R258C.

Meanwhile, both -actin and SM22a protein expression was decreased in Acta2+/- R258C
and Acta2+/- cells when compared to wild type controls, even though there were no
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changes observed in their respective RNA expression. These results suggest the decrease
of endogenous expression of Acta2 alter the pathways involved in pathogenesis60.
(Figure3.3B)

Figure 3.3 Contractile Gene and Protein Expression in Wildtype (WT), Acta2+/+ R258C
TG

, Acta2+/- and Acta2+/-

R258C TG

SMCs. A. Quantitative real-time PCR data for the

expression of the contractile genes Acta2, Myh11, Cnn1 and SM22α in all four genotypes.
Wildtype is set to 1 for each assay and gene expression in the other genotypes is
presented as a fold difference from the wildtype. All results are normalized to Gapdh. *
p<0.05, ** p<0.01. Error bars are ±standard deviation (s.d.) B. Contractile protein
expression, as shown by Western blot. SM-MHC = smooth muscle myosin heavy chain.
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SM α-actin = smooth muscle-specific α-actin. With permission60.

Formation and stability of -actin filament in SMC showed interesting differences
between all four genotypes. When treated with TGF-B1, immunofluorescene studies
showed Acta2+/+ R258C cells were able to form actin filaments, while Acta2+/- R258C showed
little filament formation and large pools of unpolymerized actin (Figure 3.4A). Actin
filament stability was then determined using and F/G actin assay. Results showed that
both transgenic cell lines lacked pelleted actin filaments. This suggests that, even though
Acta2+/+ R258C cells are able to produce actin filaments, they are not as stable as those in
wildtype cells and are disrupted by the stress and agitation required to perform the
assay60. (Figure 3.4B) Furthermore, assays done in purified wildtype and R258C actin
showed that the mutant actin had decreased motility and increased flexural rigidity, the
force required to bend a non-rigid structure to a certain curvature, which indicates the
presence of frail filaments65. Together, these results suggest a significant impact of
R258C mutation in filament formation and stability in vitro, leading to the hypothesis that
these changes might lead to aortic pathogenesis in vivo.
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Figure 3.4 SM α-actin Polymerization 72 Hours post TGF-β1 Treatment in vitro - A.
Immunofluorescent staining after 72 hours of TGF-β1 treatment for α-SMA (green) and
total filamentous actin (phalloidin, red). Nuclei were stained with DAPI (blue). B. F/G
actin assay after 72 hours of TGF-β1 treatment. Positive ctrl= wildtype cells treated with
phalloidin. U=unpolymerized. P=polymerized. With permission60
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Results
Aortic Pathology
Aortic contractility assays were performed on Acta2+/+

R258C

and wildtype mice in

collaboration with the Stull lab at University of Texas Southwestern Medical Center.
Aortas from three-month-old male mice were dissected and aortic rings of the thoracic
ascending, thoracic descending and abdominal aortas were mounted on an isometric force
device. Acta2+/+

R258C

aortas showed significantly lower contractile force generation

across the three sections compared to wildtype mice (P<0.05) 66. Therefore, it is safe to
assume that the unstable -actin filaments observed in Acta2+/+ R258C SMCs disrupt the
proper functioning of the contractile apparatus in the aortic tissue (Figure 3.5A).
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Figure 3.5 Effects of Acta2R258C Mutations in Murine Aortic Function - A. Acta2+/+
R258C

aortic rings subjected to of stimulation with KCl showed decreased force

development (contractility) throughout the whole length of the aorta when compared to
WT66. B. Representative echocardiogram images depicting an enlarged ascending aorta at
12 months of age in Acta2+/+ R258C (1.71mm) compared to WT (1.42mm)

Aortic histology and echocardiograms were used to assess disease progression in
all four genotypes (Acta2+/+, Acta2+/- , Acta2+/+

R258C

and Acta2+/-

R258C

) at 1 month, 3

months, 6 months and 1 year of age (Figure 3.5B). At the first month of age, all mice
showed normal lumen diameter and no evidence of elastic fiber disruption or
proteoglycan deposition (Figure 3.6A). A few abnormalities were observed in the aortic
wall structure, characterized by increased cell density in Acta2+/+ R258C and Acta2+/- R258C
and increased numbers of elastic lamellar layers in Acta2-/+
both Acta2+/- and wild type aortas. Acta2+/-

R258C

R258C

when compared with

aortas had an average of 10.2 elastic

lamellae compared with 9.2 and 9.4 lammellae in wildtype and Acta2+/-, respectively
(P<0.05) (Figure 3.6B). Quantitation of SMC cells per mm2 in the aortic media, show a
significant increase in cell density with 2,122 cells/mm2 and 1,758 in Acta2+/- R258Cand
Acta2+/+

R258C

aortas, respectively. In contrast, cell density in wildtype aortas was only

1,431 cells/mm2 (P<0.01). No significant difference between wildtype and Acta2+/- was
observed (Figure 3.6C). Contrary to the recorded medial thickening in the Acta2 null
model, we measured decreased medial area in both Acta2+/- R258Cand Acta2+/+ R258Caortas
during the first month of age, but no difference at 3, 6 and 12 months (Figure 3.6D).
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Positive staining of calponin 1, a SMC-specific contractile protein, confirmed that these

were indeed SMCs. There was no evidence of proteoglycan deposition or elastic fiber
disruption, two classic markers of aortic disease, at this age.
Figure 3.6 Aortic Pathology in Acta2R258C Mice - A. Aortic cross-sections of one month
old mice. Top panels (H&E stain) and bottom panels (Movat Stain) of the aortic wall
show no evidence of elastin disruption and proteoglycan accumulation.

Increased
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number of elastic lamellae can be appreciated in the Acta2+/-R258C mice. B. Quantification
of elastic lamellae at month of age confirms a significant increase in the number of
lamellae in Acta2+/-R258C aortas. C. Histological analysis of the progression of cell density
during the first year of life in mice. After the first month, both Acta2+/+R258C and Acta2+/R258C

aortas increased cell density compared to WT, but the difference dissipates at 3

months of age in Acta2+/+R258C and after 6 months in Acta2+/-R258C mice. Suggesting
excessive SMC proliferation during development but not after birth, hence the growth of
existing cells decreases cell density over time. D. Histological quantification of aortic
medial area during the first year of life. The media is significantly smaller only at the
first month time-point in both transgenic genotypes. Starting at 3 months of age, no
significant differences in the area of the aortic media are observed. E. Aortic diameters
during the first year of life measured in vivo by echocardiogram. Mean aortic
enlargement is observed in Acta2+/-R258C mice starting at 3 months of age compared to
WT. At 6 and 12 months of age, Acta2+/-R258C aortas are significantly larger than both WT
and Acta2+/- aortas. No significance was observed in Acta2+/- or Acta2+/+R258C mice, which
indicates that decreased endogenous Acta2 expression does have a deleterious effect in
aortic pathology.

Interestingly, by 3 months of age, only Acta2+/- R258C mice had enlarged thoracic
aortas by echocardiogram analysis when compared to both wildtype and Acta2+/- aortas
(P<0.05) but no significant difference was observed with Acta2+/+ R258C mice. The average
aortic diameter during late diastole of Acta2+/- R258C was 1.51 mm compared to 1.38 mm,
1.45 mm and 1.46 mm in wildtype, Acta2+/+

R258C

and Acta2+/- , respectively
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(Figure3.6E). The lack of a significant difference between Acta2+/+
R258C

R258C

and Acta2+/-

aortas is due to the high variability of aortic diameter observed within the former

cohort most likely due to epigenetic differences in the expression of the transgene. The
significant increase in cell density observed at 1 month of age was not evident in the
Acta2+/+ R258C but still present in the Acta2+/- R258C aortas by three months. Quantification
of the elastic lamellae showed no difference from the previous time point. Again, elastic
fragmentation and proteoglycan deposition was not evident in these aortas.
Aortic tissues from Acta2

+/- R258C

mice begin to show signs of medial degeneration

by 6 months of age, as the elastic lamina is thinner in these mice when compared with
both wildtype and Acta2+/-. This can be observed by a decrease in the percent medial area
composed by the elastic fibers; these fibers account for 43% of the total medial area in
Acta2+/-

R258C

aortas compared to 47% and 48% in both wildtype and Acta2+/- aortas

(P<0.05), respectively (Figure3.7A). The fact that there is not difference in total medial
area, suggests that, indeed, the difference is due to thinning of the elastic fibers and not
an increase in cellular area. It is important to notice that no changes in the number of
elastin fibers occurs after birth. Still, no significance in proteoglycan accumulation and
elastin breaks is observed in aortic histology. Interestingly, the increased cell density
persists between Acta2+/- R258C and wildtype aortas (P<0.05) even though the medial areas
show no significant difference (Figure 3.6C). No difference in cell density is observed
between the other genotypes. By this time point, we observe a greater increase in aortic
diameter of Acta2

+/- R258C

mice (P<0.01) suggesting there is, indeed, a dose dependent

effect seen by the decrease in endogenous Acta2 (Figure 3.6E).
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Analysis of elastic fibers integrity at 12 months of age shows an increase in
elastin breaks in Acta2+/+ R258C and Acta2+/- R258C aortas when compared to wildtype aortas
(P<0.05 and P<0.01). An increase in elastin breaks was only significant in Acta2+/- R258C
when compared to Acta2+/- aortas (P<0.05) (Figure 3.7B). Thinning of the elastic fibers
was also evident at this time. Another important marker of aortic disease, increased
deposition of proteoglycans in the aortic media, was observed in the Acta2+/- R258C aortic
by the first year of age when compared to both wildtype and Acta2+/- mice. There smaller
pools of proteoglycan accumulation in the Acta2+/+ R258C aortic media, but not enough to
reach a significant difference (Figure 3.7C). We should point out that a pathogenic
marker in the Acta2-/- model, medial thickening, was not observed in our mutant mice
(Figure 3.6D). By now, cell density has leveled between the 4 genotypes, suggesting that
the hyperplastic remodeling observed during development ceases in the early stages of
mice’s life and increases in medial area are mainly due to cell growth as opposed to
proliferation.
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Figure 3.7 Elastic Fiber Integrity in the Tunic Media at 12 months of age – A. Elastic
fiber thinning and degeneration is evident in Acta2+/-

R258C

mice compared to all other

genotype is demonstrated by a decrease in the percent area of the media comprised by
elastin fibers in these mice (while the total medial area is statistically insignificant across
all four genotypes). B. Both, Acta2+/+

R258C

and Acta2+/-

R258C

have more elastic fiber

breaks, and hence more severe medial degeneration, when compared to WT. Only
Acta2+/- R258C mice have significantly more breaks than Acta2+/- mice, again supporting
our theory that decreased endogenous Acta2 leads to increased pathologic severity. C.
Movat stains of aortic cross sections elucidate three clear markers of aortic disease in the
medial wall in Acta2+/-

R258C

mice: Elastic fiber thinning, elastic fiber breaks (yellow

arrows) and proteoglycan accumulation (stains blue, focal accumulation depicted by
black arrows)
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Analysis of the aortic diameter by echocardiography shows interesting results in
our last time point. As expected, at 12 months Acta2+/- R258C aortas have a significantly
larger diameter at an average of 1.67 mm, compared to 1.52 mm in wildtype and 1.57
mm in Acta2+/- mice (Figure 3.6E). The interesting observation comes when analyzing
the aortic diameter of Acta2+/+ R258C mice. These aortas average 1.62 mm, which, by itself,
would be considered a slightly “enlarged” aorta. The lack of significance is due to the
great variability observed in this genotype, with the smallest measurement being 1.47mm
and the largest 1.75mm (clearly enlarged). By comparison, the largest aortas observed in
wildtype and Acta2+/- were 1.55 and 1.59, respectively. These results suggest that the
transgene does have a pathogenic effect in the aortic wall, but the increased expression of
endogenous Acta2 in the Acta2+/+R258C mice offsets the dominant negative effect of the
mutation and induces a greater variability between mice of this same genotype. Future
experiments could focus on studying the expression of endogenous Acta2 in all four
genotypes.
Loss of Transgene Expression
Unfortunately, after the sixth generation of the Acta2 R258C transgenic mice we
discovered that the transgene was no longer expressed at significant levels. The loss of
expression was first seen in IEF blots, which only showed traces of the transgenic -actin
were being expressed from aortic lysates66 (Figure 3.8A).

46

Figure 3.8 Loss of Transgene Expression - A. IEF blots of aortic lysates show
insignificant amounts of mutant SM α-actin.

66

B. cDNA quantification PCR shows

insignificant presence of the mutant mRNA (red circle), compared to the endogenous
Acta2 mRNA.

To confirm the actual loss of the transgene expression, we synthesized cDNA
from RNA (obtained from aortic lysates). Amplification of the cDNA corroborated the
results seen at the protein level -insignificant expression of mutant Acta2. (Figure 3.8B)
A new transgenic mouse model of the Acta2 R258C mutation is currently being
generated using the novel TARGATT gene insertion system to complete our studies.
This method guarantees single gene insertion into a defined, transcriptionally-active locus
with high levels of gene expression67.
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CHAPTER 4
SMC Proliferation and Vascular Response to Injury In Vivo in Acta2 Mouse Models
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Introduction
Initially, mutations in ACTA2 were associated as a major cause of fTAAD, but
after studying the clinical history of patient families, an unexpected link was made
between aortic disease and vascular occlusive disorders such as CAD and ischemic stroke
(68). Unlike atherosclerosis, in which the occlusion is due to accumulation of plasma
lipids and inflammatory cell response, (133C) excessive SMC proliferation and migration
into the lumen of small vessels are the most likely causes of the occlusive vascular
pathology in patients with ACTA2 mutations. The hypothesis is strengthened by positive
SM -actin staining in cells occluding the lumen of epicardial vessels in a patient
carrying an ACTA2 R118Q mutation (Figure 4.1A) and the vasa vasorum in patients with
R149C mutations47(Figure 4.1B)

Figure 4.1 Vascular Occlusive Pathology in Patients with ACTA2 Mutations - A.
Epicardial vessels stenosis in ACTA2 R118Q caused by excessive SMC proliferation.
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Cells stain positive for SM alpa-actin stain in vessel lumen. B. The vasa vasorum of
patients with ACTA2 mutations is completely occluded (top panel) with cells that stain
positive for -actin (bottom panel), indicating these cells are smooth muscle-like.
Reprinted by permission from Copyright Clearance Center: Nature Genetics, copyright
(2007).

One of the most severe mutations in ACTA2 is R258C, which causes early-onset
stroke in nearly 50% of carriers47(Figure 3.1). Therefore, the transgenic Acta2 R258C
mouse model became an invaluable tool for studying the effects of this mutation in SMC
proliferation. As expected, explanted aortic SMCs from Acta2+/+ R258 and Acta2+/R258 mice proliferated more rapidly than wildtype SMCs. When comparing the first two
cell lines, Acta2+/- R258 SMC proliferated at a significantly higher rate than Acta2+/+
R258 cells. Suggesting a link between -actin filament disruption and proliferation in

SMCs60.
Figure 4.2 Phenotypic Plasticity in SMC. SMC dynamic phenotypic changes from
proliferative, migratory, secretory and non-contractile (left) to nonproliferative,
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nonmigrating, and contractile with mature focal adhesions (right)
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. Permission from

Copyright Clearance Center: NPG Genet Med (2010)
In mature vessels, SMCs are known to retain their phenotypic plasticity, ranging
from a synthetic proliferative phenotype to a quiescent contractile one 68 (Figure 4.2). In
healthy vessels, most SMCs are found in the contractile state and are characterized by
increased expression of contractile proteins organized into lattice-like filament structures.
However, SMCs can revert to a more proliferative phenotype when, in response to
endogenous and environmental factors, contractile gene expression is switched to
expression of growth and matrix generating genes69. The serum response factor (SRF) –
myocardin related transciption factor (MRTF) axis is widely accepted as the canonical
pathway driving the switch between SMC phenotypes70. SRF is a ubiquitously expressed
transcription factor responsible for the transcription of more than 200 genes. In SMCs,
MRTF-A and MRTF-B are able to move intracellularly between the nucleus and the
cytoplasm, binding to SRF while in the nucleus and preventing growth gene expression 68,
71

. Globular actin is responsible for sequestering MRTF-A in the cytoplasm - freeing

nuclear SRF to bind to other growth gene coactivators72. As previously stated, Acta2+/R258C aortic SMCs had large pools of globular -actin in the cytoplasm in vitro
compared to both Acta2+/+ R258C and wildtype cells (Figure 3.4A). Unsurprisingly,
Acta2+/- R258C SMCs showed decreased nuclear localization of MRTF-A, which
correlates with the increased levels of cytoplasmic globular actin and lower expression of
contractile proteins. Together, these findings explain the increased proliferative response
in the Acta2+/- R258C SMCs60.
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Figure 4.3 Increased SMC Proliferation after Carotid Injury Acta2-/-

Mice – A.

Acta2-/- aortas have an increased proliferative response to injury after 21 days.
Quantification of the neointimal layer area carotid ligation response shows significant
increase Acta2-/- mice. *p<0.05. B. Imatinib treatment post-ligation prevents pathologic
neointimal proliferation in Acta2-/- mice. *p<0.05 Permission from Copyright clearance
center: Oxford Journals Hum Mol Gen73.

Even though increased proliferation is seen at the cellular level in both Acta2+/+
R258C and Acta2+/- R258C SMCs, these mice did not present with spontaneous strokes
in vivo. Therefore, a different approach was required to study SMC proliferation in these
mice. Previous studies in the Acta2 null mouse used a carotid artery injury model as a
catalyst to promote SMC proliferation. This model is commonly used to study SMC
proliferation and migration in response to injury73. Three weeks post-ligation, Acta2-/mice showed evident increase in SMC proliferation represented by an exaggerated
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neointimal formation and intima/media ratio compared to wildtype mice (Figure4.3A).
Furthermore, treatment with Imatinib, a tyrosine kinase inhibitor use for treatment of
various cancers, prevented excessive SMC proliferation after injury in Acta2 null mice
(Figure4.3B). Based on these studies, we decided to adopt this same injury model to
study SMC proliferation in the Acta2 transgenic mice73.

Role of Bone Marrow Derived Stem Cells in Vascular Wound Healing

Following vascular injury, bone marrow derived stem cells are recruited and take
residence in the neointima to assist in the healing process. These cells differentiate into
SMC-like cells, expressing copious amounts of SM -actin, but are missing other key
markers of fully differentiated SMCs. It is thought that these newly formed
myofibroblasts aid in constricting of the elements in the thrombus formed by the
inflammatory response74-76. Without a functioning contractile apparatus, i.e Acta2
mutations, healing of the thrombus might be delayed or even fail, leading excessive
immunological and proliferative response, running the risk of completely occluding the
vessel lumen

Results
In vivo SMC Proliferation in Acta2 R258C Transgenic Mouse Models
Left carotid artery ligations were performed in 8-week-old wildtype, Acta2+/+
R258C and Acta2+/- R258C mice to determine if the disruption of actin filaments seen in
SMCs also affects the cellular proliferative response in vivo. Three weeks post ligation,
histopathological analysis of the left carotids showed excessive proliferation in the
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Acta2+/- R258C mice when compared to the other two genotypes (Figure 4.4A). The
assessment was based on total area of the neo intima, media and neointima/media ratio.
At site of with most significant occlusion, Acta2+/- R258C carotids had an increased
medial area, compared to both Acta2+/+ R258C and wildtype carotids. Total neointima
area and neointimal/media ratio were also significantly increased in Acta2+/- R258C
mice (P<0.01 and P<0.05, respectively compared to wildtype), even when the medial
area was significantly increased in these mice as well (Figure 4.4B). There was no
significance found between Acta2+/+ R258C and wildtype mice, probably due to epigenetic
differences in the transgene expression. Mutant gene expression has not yet been
quantified to address this hypothesis.

Figure 4.4 Neointimal Proliferation after Carotid Ligation Injury - A.
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Representative images of carotid cross-sections 10μm from the ligation site. The
excessive proliferative response forming the neointima and occluding the lumen can be
appreciated in the Acta2+/- R258C ligation. B. Quantitative analysis of the carotid crosssections 21 days post-injury. Increased area of the media is observed in Acta2+/- R258C
mice compared to WT. More importantly, neointimal area and media:intima ratio is
significantly larger in Acta2+/- R258C than the other two genotypes. No significance was
observed between Acta2+/- R258C and WT mice, mainly due to the large variation seen in
the Acta2+/- R258C cross-sections.

Serial sectioning from the site of ligature to the branchpoint of the ascending
aorta, subjecting every 150 m to H&E staining, allowed us to construct a map of the
varied proliferative response along the length of the carotid. We found that in wildtype,
Acta2

+/+ R258C

and Acta2

+/-

mice, most of the thrombotic and proliferative response to

the lesion had resolved. In contrast, the Acta2+/- R258C carotids presented an
exaggerated poor thrombus resolution, characterized by a dense population of
proliferative cells in the luminal area, in the first 1.9 mm proximal to the ligation site
(p<0.01) (Figure 4.5). These results complement the increased proliferative nature of
Acta2

+/- R258C

SMCs observed in vitro. Furthermore, the results suggest the decrease

in endogenous Acta2 along with the dominant negative effect of the R258C mutation
cause an increase in cell proliferation and disrupt mechanisms involved in post-injury
thrombus resolution.
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Figure 4.5 Representative Images of Serial Sectioning Starting at the Carotid
Ligation Site 21 Days After Surgery. From left to right, each panel represents a crosssection 150μm away from the previous one. The unresolved, and still active thrombus
(neointima) can be observed in the Acta2+/- R258C ligations, corroborates the critical role
Acta2 plays in wound healing. The uncontrolled proliferative response and poor thrombus
resolution may lead to arterial stenosis and strokes in patients with ACTA2 mutations.

Bone Marrow Stem Cell Replacement Therapy in vascular injury model of Acta2-;- mice
*Originally, we planned to perform the following studies in our Acta2 transgenic mouse model,
but due to the loss of transgenic -actin expression we decided to use the Acta2 null model instead.
Published work done in this model shows a similar response to carotid injury ligations73.

We believed it was necessary to repeat the carotid ligation studies in the Acta2-/-mice to
establish a reliable baseline for the bone marrow stem cell treatment. To confirm the
absence of -actin alters vascular healing and induces an excessive proliferative response
after injury by carotid ligation, we ligated left common carotid arteries from 10-week-old
mice and harvested the arteries at post-operative day 21. We serially sectioned the entire
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length of the vessels from the ligature site down to the proximal branchpoint from the
ascending aorta and stained the coss-sections every 150 m with H&E. As expected, our
results replicated our previous observations, in which Acta2-/- mice display signs of
active and proliferative thrombus organization invading the luminal area. In contrast,
wildtype carotids present a more mature neointimal lesion, occupying a significantly
smaller area of the lumen73 (Figure 4.6).

Figure 4.6 Increased Proliferative Response in Acta2-/- Carotids Post Ligation. We
were able to replicate previous results by C. Papke in the Milewicz Lab, and showed
increased neointimal formation in Acta2-/- mice in order to establish a baseline for the
bone marrow transplant experiments.

Following carotid artery injury, bone marrow derived stem cells are recruited and
take residence in the neointima to assist in the healing process. Most of these cells
stained positive for -actin, but not other markers of fully differentiated SMCs74. To test
the role of a-actin in the vascular healing process, we reconstituted the bone marrow of
wildtype and Acta2-/- mice with GFP+ wildtype cells. Carotid ligations were performed 4
weeks after bone marrow transplant. Cells in the neointima stained positive for GFP in
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both wildtype and Acta2-/- carotids. Some of the GFP+ cells also expressed -actin in
Acta2-/- mice, proving the active role of bone marrow derived cells in thrombus
resolution (Figure 4.7A). Surprisingly, there was still a significantly larger thrombus
(neointima) and percent stenosis in the Acta2-/- compared to wildtype vessels
Comparison between control Acta2-/- and Acta2-/- mice with the reconstituted bone
marrow showed no significant difference in thrombus resolution. (Figure4.7B)

C
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Figure 4.7 Vascular Response to Injury After Bone Marrow Transplant – A. GFPtagged exogenous WT bone marrow stem cells are present in the neointima of irradiated
WT and Acta2-/- mice (brown stain), confirming successful bone marrow transplant. B.
Representative images of carotid cross sections after bone marrow transplant and carotid
ligation. The wildtype phenotype was not rescued by the presence of exogenous WT stem
cells in the neointima. C. Quantitative analysis of carotid stenosis and neointimal area in
control (non-irradiated) and irradiated (bone marrow transpant) mice. Increased
neointimal area is evident in the Acta2-/- mice (top panels) when compared to WT mice.
There was no significant decrease in the neointimal area of the Acta2-/- mice that
underwent bone marrow transplant (irradiated) compared to control Acta2-/- mice,
indicating that the role of Acta2 in bone marrow stem cells is not crucial for vascular
repair. Similar results are seen for percent stenosis (bottom panels), in which the WT was
not recovered after bone marrow transplant.

Infiltration of inflammatory cells is a crucial component of the wound healing
process.

During the initial inflammatory phase, the presence of neutrophils and

macrophages initiates the recruitment of fibroblasts77,
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. Therefore, lesser activity of

inflammatory cells is expected in latter stages of the healing process.

Segments of the

carotids containing thrombi were immunoprobed with Mac-2, a marker for murine
macrophages. As expected, wildtype carotids contained a low number of macrophages in
the residual thrombi, while high macrophage activity was observed in Acta2-/- carotids
(Figure 4.8). Interestingly, irradiated carotids showed increased macrophage activity in
both WT and Acta2-/- compared to non-irradiated controls. No difference was observed
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between between irradiated WT and Acta2-/-, which suggests increased stress in the
vasculature due to radiation exposure. Our results suggest the absence of -actin has a
negative effect in the healing process after injury.

Figure 4.8 Inflammatory Response After Carotid Ligation. Few macrophages are
observed in the control (non-irradiated – top left) WT, indicating the thrombus is in its
final stages of healing. In contrast, the abundant macrophages (brown stain) in the control
(non-irradiated – bottom left) Acta2-/- mice advocates the presence of an active,
unresolved thrombus. Similar results were expected in the irradiated (bone marrow
transplant – right) mice, but the control WT phenotype was not rescued. In fact, a dense
concentration of macrophages is present in the irradiated WT type, possibly due to
lingering inflammatory effects of radiation in the vasculature.
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Overall, these results indicate that, even though SM -actin positive bone marrow
derived cells play an active role in the neointima, the recovery of -actin in these cells
was not enough to attenuate the pathological response to injury. Most likely, Acta2
deficient cells (fibroblasts, SMC) migrating for the vascular wall play a more significant
role in the wound healing process.
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CHAPTER 5
Cerebrovascular Characterization of the Acta2-/- Mouse Model
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Introduction
Moyamoya disease (MMD) is characterized by stenosis of the distal internal carotid
artery and arteries of the Circle of Willis along with growth of a weak vascular network
providing collateral flow. In angiography, these neovessels have the “puff of smoke”
appearance, which translates to moyamoya in Japanese.

There are two peaks in

incidence, during the first decade of life and a second one in patients during their third
and fourth decades79. Patients with MMD have a high risk of ischemic stroke recurrance,
thus its characterization and accurate diagnosis is vital for adequate treatment. As many
as 10% of non-syndromic MMD cases involve a family history, with increased incidence
in Asian Americans compared to Americans of Europeans decent, suggesting a strong
genetic predisposition to the disease79.
Mutations in ACTA2 have been linked to MMD, with 50% of carriers of the
R258C mutation presenting classic markers of the disease 49. Furthermore, a de novo
mutation in ACTA2, R179H, was initially was associated MMD in children, but after
examination of patient histories found some features distinguishing from the classic
disease presentation. Mainly, vessels with R179H mutation had a combination of ectasia
and stenosis, absence of collaterals and strait arterial course by angiograph examination
(Figure 5.1A). Histological analysis of dural vessels showed abnormalities, characterized
by intimal thickening and elastin deposition58 (Figure5.1B). Interestingly, R258C/H
mutation carriers also lacked collateral vessel formation, but no evidence of straight
arterial course was observed58.
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Figure 5.1 Cerebrovascular Abnormalities in Patients with ACTA2 Mutations – A.
Internal carotid artery injections of a cerebral angiogram of (Left) an unaffected 3-yearold child, (Right) a child with ACTA2 Arg179H is and (Bottom) a child with idiopathic
moyamoya disease. Distinctive cerebrovascular features of ACTA2 mutations with
dilatation of the proximal internal carotid artery, occlusive disease of distal intracranial
circulation, an abnormally straight course of intracranial arteries and absence of
‘moyamoya’, other basal and leptomeningeal collaterals, which are prolific i the child
with moyamoya disease B. The images show representative small arterial dural vessels
stained with H&E, elastin Van Gieson and smooth muscle actin in patients with ACTA2
R179 mutations. There is thickening of the intima, which is most prominent in Patient 1
but subtle in Patients 7 and 8. There is focal intimal thickening with deposition of elastin
(black on the elastin Van Gieson). There is focal reduplication of the internal elastic
lamina in Patient 7. Permission Copyright Clearance Center: Oxford Journals Brain58

Many challenges arise when studying MMD pathogenesis in human, including the
limited amount of patient samples and the fact that most are acquired at the end-stages of
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the disease. Based on the mutations described above, disruption in -actin plays a key
role in MMD pathogenesis. Therefore, we opted to study the cerebral vasculature in the
Acta2-/- mouse, which provides an accurate model on how deficiencies in Acta2 may
lead to cerebral vascular pathogenesis.

Results
Cerebrovascular imaging and Histopathological Analysis of Acta2+/- and Acta2-/- mice
Volume-rendered images of the Circle of Willis (CW) and nearby vessels in three
mice from all three genotypes, WT, Acta2+/-, Acta2-/- are illustrated in (Figure 2A). While
the wild-type (WT) mice exhibit essentially normal vasculature for this stage of
development, both the Acta2+/- and Acta2-/- mice exhibit distinct morphological
differences in the vessels in and around the CW. First, there is evidence for progressive
straightening of the vessels with change in genotype from WT to Acta2+/- to Acta2-/-, as
observed in the ICA (Figure. 5.2A, labelled (a, d and g)). Similarly, there is evidence for
narrowing and/or obstruction of vessels (shown by label b in WT), illustrated in the
basilar artery in the Acta2+/- mice (e) and at the branching of the basilar into the left and
right superior cerebellar artery (SCA) in the Acta2-/- mice (h). Additionally, the overall
width of the CW narrows as one progresses from the WT to Acta2+/- to Acta2-/- (labelled
c, f, and J) CT images of a curved multiplanar reconstruction of an occluded region of
the SCA in an Acta2-/- mouse shows decreased flow in the artery and a crescent shaped
lumen on cross sectional imaging, while other arteries nearby without evidence of
decreased flow show a round lumen on cross section (Figure 2B).
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Figure 5.2 Volume Rendered Images of the Circle of Willis - A. Volume rendered
images of the CW in three representative mice: WT, Acta2+/-, and Acta2-/-. Characteristic
phenotypic features of the heterozygous and knockout animals are evident and marked by
arrows: (a,d,g) straightened vessels in the Acta2 mutant mice compared to WT; (b,e,h)
narrowed or obstructed vessels in the Acta2 mutant mice compared to patent vessels in
WT; (c,f,j) narrowed CW in the Acta2 mutant mice compared WT. (B) CT images
illustrate a curved multiplanar reconstruction of an occluded region of the SCA in an
Acta2-/- mouse (Right panel). Cross sections at locations p1, p2 and p3 are shown in the
three panels to the right. Panel p2 shows a partially occluded SCA while p1 and p3 show
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normal open lumens of other arteries. In the left panel, a curved multiplanar
reconstruction of an occluded region of the Basilar artery in an Acta2+/- mouse. Panel p1
and p2 show a crescent shaped occlusion of the arterial lumen, while p3 shows a
completely unobstructed lumen. Images provided by Dr. Annapragada’s Laboratory.

Morphometric analyses for each of the

arterial narrowing, curvature

measurements and CW width parameters were performed and the results are shown in
Tables 1 and 2. For each measured parameter, three comparisons were made between the
following: WT vs. Acta2+/-, WT vs. Acta2-/- and Acta2+/- vs. Acta2-/-.The vessel radii are
significantly decreased in the right and left ICAs of the Acta2-/- mice compared to both
Acta2+/- and WT mice. Arterial straightening and decreased tortuosity is evident in the
right superior cerebellar artery (SCA) and left ICA of Acta2+/- and Acta2-/- mice
compared with WT, as determined by decreases in the Middle Curvature and Arc-length
ratio, respectively (Table 1 – for clarification on the parameters mentioned please refer to
methods section).

Interestingly, these same parameters in the left posterior cerebral

artery (PCA) are only different between the WT and the Acta2+/- mice, but not the Acta2/-

mice. The right PCA demonstrates a significant narrowing in the Acta2-/- mice. Sporadic

differences in length are noted, with the most significant being in the left ICA. The
circularity, and aspect ratio, measures of how circular and symmetric the cross sections of
the vessels are, do not show statistically significant variation with genotype, suggesting
that in spite of the other morphological changes, the vessels are retaining their
intrinsically circular cross sectional shape. Finally, the lower-half area and the basal
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triangle area of the CW are significantly smaller in the WT than the Acta2+/- and Acta2-/mice (Table 2).

Table I. Statistical differences in the dimensions of cerebrovascular arteries on CT
imaging in the WT, Acta2+/- and Acta2-/- mice.
Vessel

Radius

Length

Middle
curvature

Arc/Length
ratio

Narrowing
count

WT vs. Acta2+/-

0.54

0.61

0.84

0.47

0.72

Mean
aspect
ratio
0.17

Acta2+/- vs. Acta2-/-

0.00
0.01

0.69

0.69

0.33

0.71

0.11

0.95

0.45

0.10

0.33

0.95

WT vs. Acta2+/-

0.47

1.00

0.21

0.54

0.38

0.84

Acta2+/-

0.27

0.69

0.86

0.86

0.73

0.29

0.37

0.04
0.00

0.33

0.37

WT vs. Acta2+/-

0.68

0.21

0.68

0.11

0.53

1.00

Acta2+/-

0.09

0.14

0.95

0.07

0.03
0.01

0.90

0.14

0.02
0.02

0.46

0.73

WT vs. Acta2+/-

0.30

0.25

0.84

0.84

0.45

0.84

Acta2+/- vs. Acta2-/-

0.07

0.27

0.61

0.39

0.21

0.39

0.45

0.53

0.29

0.37

0.47

0.00

WT vs. Acta2+/-

0.76

0.07

0.99

0.02

0.02
0.02

0.46

0.27

0.27

0.86

0.02

0.00
0.05
0.00

0.01

Acta2+/-

0.01

0.35

0.14

WT vs. Acta2+/-

0.07

0.03

0.00

0.01

0.20

0.25

Acta2+/- vs. Acta2-/-

0.14

0.18

0.14

0.07

0.17

0.78

0.53

0.29

0.10

0.84

0.98

0.45

WT vs. Acta2+/-

0.41

0.76

0.68

0.54

0.91

0.68

Acta2+/-

0.14

0.61

0.95

0.39

0.54

0.78

0.63

0.95

0.95

0.10

0.38

0.53

WT vs. Acta2+/-

1.00

0.30

0.41

0.54

0.42

1.00

Acta2+/-

0.33

0.46

0.95

0.86

0.64

0.22

0.23

1.00

0.29

0.73

0.92

0.45

Right Internal Carotid

WT vs.

Acta2-/-

Right Posterior Cerebral Artery
vs.

Acta2-/-

WT vs. Acta2-/-

0.53

Right Superior Cerebellar

WT vs.

vs.

Acta2-/-

Acta2-/-

Right Anterior Cerebral

WT vs.

Acta2-/-

Left Internal Carotid
vs. KO

WT vs. KO
Left Posterior Cerebral

WT vs.

Acta2-/-

Left Superior Cerebellar
vs.

Acta2-/-

WT vs. Acta2-/Left Anterior Cerebral

WT vs.

vs.

Acta2-/-

Acta2-/-

In all cases, null hypotheses H0: WT=Acta2+/-, H0: WT=Acta2-/-, H0: Acta2+/-=Acta2-/- were tested. For the radius,
length, and mean aspect ratio measures, the alternate hypotheses were H1: WT>Acta2+/-, H1: WT>Acta2-/-, H1: Acta2+/>Acta2-/-. For the middle curvature, arc/length ratio and narrowing count measures, the alternate hypotheses were: H 1 :
WT<Acta2+/-, H1: WT<Acta2-/-, H1: Acta2+/-<Acta2-/-.. The Wilcoxon Rank-Sum test was used to assess statistical
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significance. Bolded entries indicate measures where the null hypothesis was disproven at the 95% confidence level.
Entries in italics were non-significant. The complete analysis of variance is presented in the supplemental data section.
Analysis provided by Dr. Annapragada’s Laboratory at Texas Children’s Hospital.

Table II. Statistical differences of the dimensions in the Circle of Willis by imaging in
the WT, Acta2+/- and Acta2-/- mice.*
Circle of Willis

Total Area

Upper
Area

WT vs. Acta2+/-

0.02

0.92

Acta2+/-

0.46
0.45

vs.

Acta2-/-

WT vs. Acta2-/-

Half

Lower
Area

Half

Basal
Triangle Area

Width

Narrowing %
of all COW
vessels

0.01

0.01

0.35

0.27

0.09

0.53

0.61

0.39

0.47

0.10

0.00

0.00

0.00

0.04

For the total area, upper half area and width, the null hypotheses H 0: WT=Acta2+/-, H0: WT=Acta2-/-, H0: Acta2+/=Acta2-/- were tested while the alternate hypotheses were H1*Acta2+/-, H0: WT=Acta2-/-, H0: Acta2+/-=Acta2-/- In all
cases, the Wilcoxon Rank-Sum test was used to assess statistical significance. Bolded entries indicate measures where
the null hypothesis was disproven at the 95% confidence level. Entries in italics indicate measurements where the null
hypothesis was not disproven. The complete analysis of variance is presented in the supplemental data section.
Analysis provided by Dr. Annapragada’s Laboratory at Texas Children’s Hospital.

Taken as a whole, the data suggest that narrowing and straightening of the
cerebral vessels, and a distinct narrowing of the diameter of the CW, occur with loss of
SM α-actin. The ICAs differ in more parameters than any of the other vessels, exhibiting
narrowing, straightening, and lengthening.
Histologic analyses of Acta2+/- and Acta2-/- brains show thickening of the walls of
the arteries independent of size when compared to the WT brains (Figure. 5.3A).
Immunostaining of a SMC-specific marker (calponin-1) indicated that the wall thickening
involved SMCs in the medial layer of the artery. Similarly, immunostaining for CD31
(endothelial cell marker) and Movat pentachrome staining of elastin (stains black) show
the thickening of the wall does not involve the endothelial layer and is outside the
internal elastic lamellae. To confirm the thickening of the medial layer of the arteries in
the Acta2 mutant mice, the wall-to-lumen ratio and percent wall thickness was calculated
and found to be significantly greater in Acta2+/- and Acta2-/- compared to WT for
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cerebrovascular arteries of different sizes (Figure 5.3B; p<0.05 for all analyses between
the WT and Acta2 mutant mice for all arteries > 100μm in diameter). Both vessel groups
showed significant difference nonparametric testing. In this pairwise multiple
comparisons, there was no difference between the Acta2+/- and Acta2-/- wall-to-lumen
ratio or percent wall thickness of arteries.

Figure 5.3 Histological comparison of cerebral arteries (diameters 100-200bμm
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and >200 μm) from WT, Acta2+/-, and Acta2-/- mice - A H&E staining of arterial
cross-sections. Arteries of similar diameter were analyzed according to their genotypes.
Regardless of vessel size, the walls of intracerebral arteries from the Acta2 mutant
mice appear markedly thickened compared with WT arteries. B. Morphologic analysis
of cerebrovascular pathology in WT, Acta2+/- and Acta2-/- mice. Left column: wall-tolumen ratio. Right Column: percent wall thickness. In both medium (diameter 100200μm) and large (diameter >200μm) vessels, wall-to-lumen ratio and percent wall
thickness of Acta2 mutant mice was significantly greater than that of WT group (* =
p<0.05). C. Smooth muscle cell density in the medial layer of circular vessels in WT
and Acta2-/- mice. (Top Panel) EC: Endothelial cells. SMC density was calculated by
measuring the number of SMC nuclei in the media layer of the arterial cross-sections.
(Bottom panel) WT group had a significantly lower cell density than Acta2-/- group.
This finding is highly suggestive of medial SMC undergoing hypertrophy rather than
hyperplasia.

Analysis of wall thickness in smaller arterioles (short diameter <100μm) in the
cerebral parenchyma showed a significantly higher percentage of thickened vessels in
both Acta2+/- and Acta2-/- , compared to WT (Figure 5.4B; p<0.05). No significant
difference in number of thickened vessels was observed between Acta2+/- and Acta2-/mice.
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Figure 5.4. Histological comparison of arterioles (diameter < 100μm) in the cerebral
parenchyma of WT, Acta2+/-, and Acta2-/- mice – A. Representative images for the
classification of normal and thickened vessels. B. Calponin staining of cerebral crosssections shows significant arterial wall thickening in both Acta2 mutant genotypes.
Arrows denote vessels < 100μm in diameter.

To determine whether SMC proliferation or hypertrophy was driving medial layer
thickening, the cell density of the medial layer of circular vessels from WT and Acta2-/mice was assessed. This analysis showed significantly increased cell density in the WT
compared to the Acta2-/- mice (p<0.001; Figure 5.3C). This finding suggests that the
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medial SMCs in the cerebrovascular system in the Acta2-/- mice have undergone
hypertrophy rather than hyperplasia.
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CHAPTER 6
Discussion
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Discussion
Aortic Pathology in ActaR258CMouse Model
Previous studies linked TAAD, stroke and other vascular diseases to mutations in
a single gene, ACTA2. Analysis of aortas from these patients revealed classic markers of
end-stage aortic disease including contractile fiber degradation, SMC disarray,
proteoglycan accumulation and increased medial thickness. Furthermore, these patients
presented occlusive vascular lesions in smaller vessels, which we hypothesize to be the
cause of strokes47-49. Due to the challenges involved in studying disease progression in
humans, we engineered a mouse model with an Acta2+/+ R258C mutation60. We chose this
alteration based on the severe phenotypic presentation of vascular disease in patients,
primarily early onset strokes (<20 yoa) and TAAD49. We expected this mutation to have
a dominant negative effect and therefore mimic the human pathogenic phenotype in our
mouse model. Additionally, we hypothesized that a decrease in endogenous expression of
Acta2 would increase the severity of the observed phenotype. Initial studies of ex-vivo
aortic rings confirmed decreased contractile force development in Acta2+/+

R258C

aortas

compared to wildtype66. . The mutation lies within the SD4 domain, which plays an
important role in opening/closing of the nucleotide binding cleft. When ATP/ADP is
bound to actin, the nucleotide binding cleft interacts allosterically with the DNase
binding loop causing conformational changes during contraction. A disruption of the
cleft might explain the significant decrease in contractile force generation80. To further
support our claim, we assessed the capability of Acta2+/+

R258C TG

and Acta2+/-

R258C TG

SMCs to form functional α-actin filaments. Immunofluorescent imaging showed
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monomeric pools of -actin Acta2+/- R258C TG SMCs with little to no filament formation
even after treating with TGFB1. Acta2+/+ R258C TG SMCs did form -actin filaments. An
F/G actin assay was then performed and results showed both cell lines lacked pelleted
filaments. This suggested that, even though Acta2+/+ R258C TG SMCs are able to produce
filaments, they are weaker than those in wildtype SMCs and the shear stress of the assay
was enough to cause significant disruption60. Therefore, we can safely conclude that the
R258C mutation not only causes structural instability, but also affects interactions
between actin monomers leading to severe disruptions in the contractile apparatus.
Moreover, these results may translate in vivo where mechanical stress and other
differentiating factors may lead to filament formation and stabilization, decreasing the
potential deleterious effects of the mutation on the aortic wall.
The aortic phenotype in the mouse model did not present with the same degree of
severity as observed in SMCs in vitro, but the results gave us valuable insight into the
underlying mechanisms and factors involved in aortic wall degeneration and aneurysm
formation.

As early as 4 weeks of age, we can observe significant developmental

differences between mutant and wildtype mice. There was an increase in the number of
elastin layers laid down during development and density of SMCs in both Acta2+/+ R258C
and Acta2+/- R258C mice. Elastin plays a crucial role in aortic capacitance in response to
flow, which is also regulated by the contractile properties of the SMCs in the aortic wall.
Interestingly, similar aortic pathology was observed in the hemiygous ELN mice, the
gene that encodes for elastin protein. These mice had a 50% decrease in elastin protein
expression as well as increased SMC proliferation and an increased number of thinner
elastic lamellae at birth. The aortic extensibility at physiological pressures is normal,
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suggesting that the increase in elastic lamellae is due to decreased elastin protein
expression and helps maintain normal levels of aortic extensibility81. Therefore, an
increase in the number of elastic fibers in the Acta2 mutant mice may be associated with
a physiological response to compensate for the decreased contractile force generation of
SMCs and the aortic wall contractile apparatus as a whole. The increased number of
SMCs may also be due to a compensatory proliferative response, which will be discussed
later in this chapter. The fact that the number of elastin layers remained constant during
the mice’s lifespan, and that there is no evidence of continued proliferation after birth,
indicates that modifications in the elastin lamellae occur during development.
The compensatory mechanisms described above proved to be insufficient in
maintaining the aortic wall integrity and by 3 months of age, we observe a 9% increase in
the average aortic diameter in Acta2+/- R258C mice when compared to both wildtype. By
12 months of age there is an average increase of 10% in aortic diameter compared to
wildtype and a 6% increase compared to Acta2+/-.

Even though the average increased

only 1% over that period of time, a more significant difference is observed in the range of
aortic diameters. The Acta2+/+R258C did not show a significant increase in the average
aortic diameter, mainly due to the wide range of diameters observed within the cohort.
Of notice is the fact that the largest diameter observed in an Acta2+/- R258C mouse and an
Acta2+/+ R258C were 1.81mm and 1.75mm, respectively. These are clearly enlarged aortas
when compared to the maximum diameter observed in Acta2+/- (1.59mm) and wildtype
(1.55mm) mice. The variability in Acta2

+/+ R258C

is to be expected, based on the variable

penetrance observed in patients with the same ACTA2 mutation48. The variability in the
phenotype can also be attributed to epigenetic changes in transgene expression, which we
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were planning to test for before we lost expression of the mutant gene in the mice.
Nevertheless, these results confirm that the mutant Acta2 plays a critical role in the aortic
enlargement observed in our mouse models. We believe one of the possible triggers of
the pathogenic enlargement relates to the results of the F/G actin assay in vitro, in which
the shear stress of the assay disrupted the filaments formed in Acta2

+/+R258C

SMCs.

Correspondingly, the stress caused by the force of pulsatile flow in the ascending aorta
has a similar effect on actin filament integrity in the SMC in the aortic wall. In fact,
increased blood pressure caused surgical constriction of the aorta in mice can lead to
increased root diameter and alterations in AT1 signaling; a similar pathway to the one
observed in the Marfan mouse model82-84. We began testing this hypothesis by inducing
hypertension in our mutant mice, an important risk factor associated with aortic disease.
Unfortunately we were unable to complete these studies because we lost expression of
the transgene in these mice.
Histological analysis of aortic tissue showed elastic fiber straightening, thinning
and fragmentation along with proteoglycan accumulation in Acta2+/- R258C mice compared
to both Acta2+/- and wildtype mice. We first observed elastic fiber thinning at the 6month
time point without significant number of elastin breaks or proteoglycan accumulation.
The weakening of these fibers progressed to increased breaks and accumulation of
proteoglycans by 12 months of age. These features resemble the end-stage of aortic
disease in tissue from individuals with ACTA2 mutations and are considered classical
markers of aortic wall degeneration (Figure 1.2) Atypical features in the aortic wall of
these patients, such as focal areas of increased numbers of SMCs, were also present in
Acta2+/- R258C mice47. A recent study linked pregnancy in women with ACTA2 mutation to
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increased risk of acute aortic dissections with minimal aortic degeneration. Accumulation
of proteoglycans in the aortic wall was the common pathologic feature found in these
cases of acute dissection85. Previous studies have suggested proteoglycan accumulation
decreases tensile strength of the aortic wall, which could lead to aneurysm formation and
rupture86. Interestingly, this study showed proteoglycan accumulation in pregnant women
with Acta2 mutation happens independent to medial degeneration, while in our mouse
model we observed this phenomenon was preceded by elastin degeneration. Leading us
to conclude that, even though these are both markers of aortic disease, they most likely
develop through separate mechanisms. Future studies could determine if the presence of
both defects have a synergistic effect on aortic wall debilitation. It would be of interest to
determine if proteoglycan accumulation alone is enough to increase the risk of aortic
dissections in all patients with ACTA2 mutations. In addition, 63% of the women who
suffered acute aortic dissection also had a history of hypertension, providing further
evidence that ACTA2 mutations decrease the aortic wall’s ability to effectively withstand
the stress of pulsatile flow85.

Fibrotic and Proliferative Response to Injury in Acta2 mutant Mice
ACTA2 mutations cause a shift in SMC phenotype from a quiescent/contractile to
a more proliferative state.

This was first seen in SMCs from patient explants that

presented with decreased SM -actin filament formation and increased proliferation60, 73.
Some patients with ACTA2 mutations suffered from vascular occlusive diseases
characterized by increased number of SMCs invading the vessel lumen. Mutated -actin
promotes excessive proliferation and occlusion of smaller arteries, contrary to its effect
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on larger vessels in which the mutant protein compromises aortic wall integrity and leads
to aneurysm formation. Uncontrolled proliferation, and not atherosclerotic lesions, is
believed to be the main cause of stroke and CAD in patients with ACTA2 mutations.
Complete proliferative occlusions can be seen in the vasa vasorum in the aortic wall of
these patients supporting our claim that the invasion of SMCs into the lumen can lead to
widespread vascular occlusive diseases48, 49, 58, 87, 88.
Although great advances have been made recently to understand the underlying
mechanisms of SMC proliferation in vitro, the triggering factors promoting a shift to the
proliferative state in vivo are poorly understood. The Acta2 R258C transgenic mice do not
stroke spontaneously, limiting our ability to study SMCs in vivo under physiological
conditions. To overcome this limitation, we adopted the carotid injury model as a
mechanism to study the proliferative response of SMC in vivo. Previous studies on
Acta2 knockout mice used the same model and observed increased proliferation of SMCs
invading the lumen causing significant stenosis73. Similar pathology was observed in
Acta2+/-R258C mice after injury. In most of these mutant vessels, the carotid lumen was
occluded by a large fibroproliferative thrombus that failed to resolve 3 weeks after
surgery, which we will refer to as neointima. Our results show no indication that the
initial inflammatory response - characterized by macrophage infiltration, stem cell
migration and increased number of recruited myofibroblasts to the injury site - was
altered in the Acta2+/-R258C mouse model. This is followed by a proliferative stage, in
which myofibroblasts and SMCs secrete large quantities of collagen and other matrix
proteins forming granulation tissue. At the time of sample collection, most of the
granulation tissue has resolved in both Acta+/- and wildtype carotids but it is still present
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in most the Acta2+/-R258C carotids. Therefore, we believe alterations in SM -actin
severely affect the transition to the final contractile stage77, 78, 89. Normally, SMCs and
myofibroblasts play an important role in organizing the thrombus by contracting and
promoting its resolution89. Mutations in Acta2, might then decrease the effectiveness of
the contractile apparatus, causing disorganized and decreased contraction of the
thrombus. Without the ability to contract properly, the tissue enters an uncontrolled
proliferative phase promoting the observed fibroproliferative neointimal lesion.
Supporting evidence is observed in vitro, where Acta2+/+R258C SMCs were unable to form
SM -actin filaments, differentiate, and had an increased proliferative profile compared
to wildtype cells. We believe the decreased ratio of endogenous to mutant actin in
Acta2+/-R258C SMCs is primarily responsible for this phenomenom, which eventually leads
to the uncontrolled proliferation observed in these mice60. Even though the carotid
ligation model does not mimic physiological conditions, it is still a valuable model to
study the proliferative and contractile mechanisms of SMCs, allowing us to understand
the effects of Acta2 mutations in vivo in a controlled environment.

Bone Marrow Replacement Therapy in Vascular Repair
Stem cell replacement therapy to treat genetic disorders has been gaining traction
in the medical field over the past few years. Studies show stem cells migrate to vascular
tissue after injury and differentiate into SMC-like cells, expressing common SMC
markers including SM -actin. These differentiated cells aid in the contractile phase of
wound healing similar to the action of myofibroblasts and SMCs74, 76. We hypothesized
that if the bone marrow cells in Acta2-/- mice were reconstituted with wildtype bone
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marrow, the migration of wildtype stem cells to the injury site after carotid ligation would
contribute to the stabilization of the contractile phase and prevent uncontrolled
proliferation and formation of a disorganized thrombus. According to our results,
thrombus resolution was not affected by the introduction of wildtype SMC-like cells into
the lesion. There was no significant difference between sizes of the fibroproliferative
lesions between Acta2-/- mice with reconstituted bone marrow and those that did not
receive stem cell treatment. Furthermore, we were able to confirm that wildtype stem
cells migrated to the lesion site and differentiated into SMC-like cells, evidenced by the
presence of SM -actin in the thrombus.
One possible explanation is that, even though important, the role of bone marrow
stem cells in vascular injury is not critical for vascular repair. It is possible that the
function of resident SMCs and fibroblasts migrating to the injury site, which still lacked
SM -actin, is far more important than the migration and differentiation of stem cells90.
The activity of these stem cells in the injury site was not assessed, but it is possible that
they had decreased functionality. One way to prove that is to perform ligations in the
GFP-tagged WT mouse and look at stem cells protein expression in the affected tissues.
Another possibility has to do with the type of injury inflicted in the vessel. One study
detailed the migration of stem cells to different types of vascular injury, including carotid
ligations. The author claims endoluminal denudation injuries elicit the highest migration
and differentiation response from stem cells. In comparison, carotid ligations present
relatively low numbers of bone marrow stem cells in the injury site 74. In fact,
endoluminal denudation is a more physiologically relevant model - maintains flow and
endothelial injury and endothelial injury occurs frequently in vivo - and should be
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considered for future studies. Before completely discarding stem cell therapy as a reliable
treatment option for proliferative vascular diseases in patients with Acta2 mutations, it
would be interesting to first establish the role of stem cells in thrombus resolution in
endothelial lesions.

Cerebrovascular Pathology in Acta2+/- and Acta2-/- Mice
Acta2 mutant mice exhibit cerebrovascular disease that mimics the arterial disease
found in children and young adults with ACTA2 missense mutations

48, 58

. Certain

arteries (left ICA, PCA and SCA) in the mutant mice are straighter than corresponding
arteries in WT mice, mirroring the straightening of the cerebral arteries observed in
children with ACTA2 mutations. The occlusion of the arteries in ACTA2 mutation patients
is similar to the pattern observed in MMD and primarily involves the distal ICA but often
extends to the middle and anterior cerebral arteries and can involve the posterior arteries
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. Both the Acta2+/- and Acta2-/- mice exhibit distinct morphological differences in the

vessels in and around the CW, including reduction in arterial diameter. Some Acta2-/mice also exhibit complete occlusion of some vessels. Finally, as observed in individuals
with ACTA2 mutations, the mouse model shows no evidence of compensatory collateral
blood vessel formation like that observed in typical MMD. Therefore, the Acta2 mutant
mouse models recapitulate the clinical features of the cerebrovascular disease observed in
children with cerebrovascular disease due to ACTA2 missense mutations that disrupt
R179 or R258.
Vascular remodeling results from interplay between arterial structure and luminal
pressures. In cerebral arteries, the increased intraluminal pressures from hypertension
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leads to thickening of the wall and an increase in wall thickness and wall/lumen ratio but
without growth of the artery, which generally leads to a smaller lumen and increased wall
to lumen ratio

63, 92

. Studies in the spontaneously hypertensive rats show increased

thickness of the arterial walls in a large part due to increased SMC mass, with additional
studies confirming that the increased SMC mass is due to growth of SMC’s (i.e.
hypertrophy) and not increased number of these cells (i.e., not hyperplasia)

93

. The

histologic changes in the cerebral arteries in the Acta2 mutant mice are similar to the
changes observed with hypertension in rat and mouse models, specifically the
cerebrovascular arterial walls are diffusely thicker due to hypertrophy of the SMCs.
These histologic changes are present despite the fact that the Acta2+/- mice have blood
pressure similar to WT mice and the Acta2-/- mice are hypotensive with a systolic blood
pressure 26% lower compared to WT mice

61

. Thus, the loss of SM α-actin in the

absence of hypertension triggers vascular remodeling similar to the remodeling
associated with increased luminal pressures due to hypertension.
The cerebral arteries are straighter in the Acta2 mutant mice, which raises the
questions as to why there are no reports of straightened arteries in the hypertensive
animal models if the cerebrovascular pathology is similar. The most extensively studied
animal models of hypertension are the spontaneously hypertensive rat (SHR), which
develop hypertension at 5 to 6 weeks of age, and stroke-prone spontaneously
hypertensive rat (SPSHR), which develops hypertension at 3 to 4 weeks of age

63

.

However, the apparent absence of arterial straightening in SHR and SPSHR could be
explained by the lack of detailed cerebrovascular imaging and assessment of arterial
curvature

of hypertensive rats to date.

Another possible explanation is that the
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straightening may be due to thickening of the arteries during development.

The

deficiency in SM α-actin is present in the vasculature during development in the Acta2
mutant mice but both hypertensive rat models develop hypertension after birth.
It is notable that the included pathologic analysis of randomly selected arteries
throughout the cerebrovascular circulation and did not limit the analyses to the large
arteries at the base of the brain. These analyses confirmed that the thickening of the
medial layer occurred in all sized arteries throughout the brain, including the small
arteries in the parenchyma. Children with the ACTA2 R179 mutations, the pattern of
brain injury is indicative of both large and small artery involvement

58

.

Magnetic

resonance imaging shows ischemic lesions, consistent with large arterial occlusions, but
all these children show perivascular white matter pathology. The degree of changes in
the white matter suggests the presence of small vessel disease as well. Our data confirm
that the Acta2 mice do have diffuse involvement of all sized arteries in the brain,
including the small vessels in the parenchyma of the brain.
Children and young adults with ACTA2 mutations that lead to cerebrovascular
disease can experience transient ischemic attacks and ischemic strokes

58

. Since the

Acta2-/- mice have similar pathology and imaging findings, this animal model can be used
to test treatments to decrease the narrowing of the arteries and determine the pathology
associated with total occlusion of the arteries, with the ultimate goal of providing better
treatments and preventing strokes in children with ACTA2 mutations.

Conclusion (Table 2 Supplement)
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We were able to recapitulate significant characteristics of the aortic and cerebrovascular
pathology seen in patients with ACTA2 mutations in our Acta2 mouse models, proving to
be a valuable tool to study the underlying mechanisms of vascular disease. Furthermore,
both aneurysm formation and SMC proliferative response were exacerbated by
decreasing the amount of endogenous Acta2 in our transgenic model. The severity of the
cerebrovascular pathology did not vary between Acta2+/- and Acta-/-, suggesting there is
a minimum threshold of expressed α-actin required for proper filament formation. As
observed in vitro, Acta2+/- did not reach such threshold and very little actin filament
formation was observed. Meanwhile, the Acta2 R258C mutation appears to have a
dominant negative effect, as its effects are inversely correlated to the amount of
endogenous actin in an organism. And, the inability of the Acta2-/-R258C mice to live postpartum further proves the deleterious effect of the mutation. These studies sets part of the
basis for the development of better care and potential therapeutic treatments in patients
with ACTA2 mutations.
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Table 1 Supplement Number of Mice in Each Study
Acta2+/+

WT

Acta2+/-

Acta2+/-

R258C

Aortic Histology
1 month
3 months
6 months
12 months
Aortic Echo
1 month
3 months
6 months
12 months
Carotid Ligation
no BMT
BMT
Cerebrovascular
Imaging
Histology

Acta2-/-

R258C

7
8
6
7

7
7
8
9

6
6
7
8

9
7
7
8

6
7
7
7

7
7
7
7

7
7
7
7

7
7
9
9

10
7

7

7

7
6

9
8

7
9
6
6

Table 2 Supplement Summary of Results

Increasing Severity

Proliferation
in vitro

Proliferation to
Injury

Filaments in
vitro

WT
Acta2

+/+ R258C

Acta2
Acta2

+/-

increased

No Difference

Fragile

Cerebrovasc
ular Disease

BASELINE
n/a

Medial
Degeneration

Aortic
Enlargement

Mild

No Difference

n/a

n/a

Decreased

Increased

No Difference

No Difference

+/- R258C

increased

Increased

Decreased

n/a

Severe

Increased

-/-

increased

Increased

No Filaments

Increased

Severe

Increased

Acta2

Acta2-/- R258C

Not Viable

*n/a = not available
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